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The dysregulation of protein–protein interaction (PPI) networks has been 
implicated in many diseases. Designing therapeutic small-molecule inhibitors of these 
interactions is a challenging field for medicinal chemistry. This work advances the 
techniques for discovering more potent PPI inhibitors through integration of 
computational and biochemical techniques. 
High-throughput screening using fluorescence polarization and AlphaScreen 
assays identified an acyl hydrazone-containing inhibitor of the β-catenin/Tcf4 PPI, a key 
mediator of the canonical Wnt signaling pathway. By removing the undesirable acyl 
hydrazone moiety, a new compound, 4-(5H-[1,2,5]oxadiazolo[3',4':5,6]pyrazino[2,3-
b]indol-5-yl)butanoic acid, was developed to selectively inhibit the β-catenin/Tcf4 
interaction. The ethyl ester of this compound was tested in zebrafish embryos and shown 
to inhibit Wnt signaling in vivo at 2 and 10 µM concentrations. 
Differences between the PPI interface and the active site of traditional targets add to the 
difficulty of discovering PPI inhibitors. Herein, the relationship between inhibitor 
potency and ligand burial—defined as the fraction of the solvent accessible surface areas 
of the bound over unbound ligand, θl—in the PPI surface was evaluated. A positive 
correlation between θl and inhibitor potency was discovered. However, this correlation 
was secondary to the strong nonbonding interactions. A study of five PPI targets with 
corresponding inhibitor-bound crystal structures also revealed that empirical scoring 
 iv 
functions were slightly better at identifying known inhibitors out of the putatively 
inactive test set, and the Lamarckian genetic algorithm was more successful at pose 
prediction. 
Due to the nature of the PPI surface, directly targeting the binding site may be 
difficult. A novel combination of computational methods explored the druggability, 
selectivity, and potential allosteric regulation of PPIs. Solvent mapping confirmed that 
Tcf4, E-cadherin, APC and axin use the same binding site on β-catenin in different ways.  
Evolutionary trace analysis indicated that the region surrounding W504 of β-catenin 
might be a potentially allosteric site.  Site-directed mutagenesis testing results for a 
W504I β-catenin mutant resulted in three-fold increased binding of Tcf4 to β-catenin over 
the wild-type. This new site is promising for the discovery of future allosteric inhibitors 
of the β-catenin/Tcf4 PPI. The combined results from these studies reveals ways to better 





TABLE OF CONTENTS 
 
ABSTRACT ....................................................................................................................... iii 
LIST OF FIGURES .......................................................................................................... vii 
LIST OF TABLES ...............................................................................................................x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
ACKNOWLEDGEMENTS ...............................................................................................xv 
Chapters 
1.   INTRODUCTION .........................................................................................................1 
1.1 Protein–protein interactions as drug targets .......................................................1 
1.2 β-catenin/T-cell factor 4 interaction and the Wnt signaling pathway ................4 
1.3 Previously discovered Wnt inhibitors ..............................................................10 
1.4 References ........................................................................................................14 
 
2.   DISCOVERY AND OPTIMIZATION OF SELECTIVE SMALL-MOLECULE 
INHIBITORS FOR THE β-CATENIN/T-CELL FACTOR 4 PROTEIN–PROTEIN 
INTERACTION .................................................................................................................20 
 
2.1 Introduction ......................................................................................................20 
2.2 Methods............................................................................................................25 
2.3 Results ..............................................................................................................43 
2.4 Discussion ........................................................................................................65 
2.5 Conclusion  ......................................................................................................67 
2.6 References ........................................................................................................69 
2.7 Supplementary materials of NMR spectra .......................................................76 
  
3.   HIGH-THROUGHPUT VIRTUAL SCREENING CHALLENGES AND 
CONSIDERATIONS FOR PROTEIN–PROTEIN INTERACTION INHIBITORS ........96 
 
3.1 Introduction ......................................................................................................96 
3.2 Methods..........................................................................................................103 
3.3 Results ............................................................................................................109 




3.5 Conclusion .....................................................................................................120 
3.6 References ......................................................................................................121 
 
4.   EVOLUTIONARY TRACE AND SEQUENCE ANALYSIS REVEAL INSIGHTS 
INTO CATENIN-LIKE PROTEINS: IMPLICATIONS FOR DRUG DESIGN, 
SELECTIVITY, AND POTENTIAL FOR ALLOSTERIC REGULATION .................132 
 
4.1 Introduction ....................................................................................................132 
4.2 Methods..........................................................................................................139 
4.3 Results ............................................................................................................141 
4.4 Discussion ......................................................................................................153 
4.5 Conclusion .....................................................................................................156 
4.6 References ......................................................................................................157 
4.7 Supplementary materials of real-value evolutionary trace scores .................163 
 
5.   FUTURE DIRECTIONS AND CONCLUSION .......................................................171 
 
5.1 Future directions of novel β-catenin/Tcf4 inhibitors .....................................171 
5.2 Practical applications of θl to the discovery of protein–protein interaction 
inhibitors ..............................................................................................................172 
5.3 Further validation of potential allostery of the W504 pocket ........................177 
5.4 Conclusion .....................................................................................................179 





LIST OF FIGURES 
 
Figures 
1.1 β-catenin is involved in multiple cellular pathways. .....................................................5 
1.2 Axin, APC, Tcf, and E-cadherin bind to a long groove on the ARM domain of  
β-catenin. ..............................................................................................................................8 
 
1.3 Many compounds have been developed to inhibit the β-catenin/Tcf4 PPI. ................11 
2.1 Previous β-catenin/Tcf4 PPI inhibitors. .......................................................................23 
2.2 Publications involving biological activities of the acyl hydrazone moiety. ................26 
2.3 Top high-throughput screening compounds FP and AlphaScreen assay results. ........45 
2.4 Cell-based assay results of top compounds. ................................................................46 
2.5 Further testing of 12. ....................................................................................................47 
2.6 Synthetic schemes 1 and 2. ..........................................................................................50 
2.7 FP assay results of fragmentation study.......................................................................51 
2.8 Docking and site-directed mutagenesis studies of inhibitors. ......................................52 
2.9 Synthetic scheme 3. .....................................................................................................55 
2.10 FP assay results for β-catenin/Tcf4, β-catenin/E-cadherin and β-catenin/APC PPIs.57 
2.11 Cell-based assay testing of 14. ...................................................................................59 
2.12 Results of compound 36 on transgenic zebrafish model. ..........................................61 
2.13 Synthetic scheme 4. ...................................................................................................62 
2.14 Results of 48 and 49. ..................................................................................................64 




2S.1 Compound 34 1H NMR.  ...........................................................................................76 
2S.2 Compound 34 13C NMR. ...........................................................................................77 
2S.3 Compound 35 1H NMR. ............................................................................................78 
2S.4 Compound 35 13C NMR. ...........................................................................................79 
2S.5 Compound 36 1H NMR. ............................................................................................80 
2S.6 Compound 36 13C NMR. ...........................................................................................81 
2S.7 Compound 37 1H NMR. ............................................................................................82 
2S.8 Compound 37 13C NMR. ...........................................................................................83 
2S.9 Compound 39 1H NMR. ............................................................................................84 
2S.10 Compound 39 13C NMR. .........................................................................................85 
2S.11 Compound 40 1H NMR. ..........................................................................................86 
2S.12 Compound 40 13C NMR. .........................................................................................87 
2S.13 Compound 44 1H NMR. ..........................................................................................88 
2S.14 Compound 44 13C NMR. .........................................................................................89 
2S.15 Compound 46 1H NMR. ..........................................................................................90 
2S.16 Compound 47 1H NMR. ..........................................................................................91 
2S.17 Compound 48 1H NMR. ..........................................................................................92 
2S.18 Compound 48 13C NMR. .........................................................................................93 
2S.19 Compound 49 1H NMR. ..........................................................................................94 
2S.20 Compound 49 13C NMR. .........................................................................................95 
3.1 Illustrated example showing the differences in ligand burial.  ..................................102 
3.2 Structures and biological activities of MDM2/p53 PPI inhibitors.............................104 




3.4 Structures and biological activities of Bcl-XL/BH3-domain PPI inhibitors. .............107 
3.5 Correlation between inhibitor burial and ligand potency. .........................................110 
3.6 Comparison of the docked poses generated by Schrodinger Glide and AutoDock  
Vina. .................................................................................................................................113 
 
3.7 Correlation between docking score and ligand burial................................................116 
4.1 Binding mode of Tcf4, APC, and E-cadherin in β-catenin hot region 1. ..................134 
4.2 Probe interactions from solvent mapping the different crystal structures of  
β-catenin. ..........................................................................................................................143 
 
4.3 The ET results are visualized on the β-catenin crystal structure 2GL7. ....................145 
4.4 The region surrounding W504 has residues which are potentially functionally  
important. .........................................................................................................................146 
 
4.5 Comparison of Probe changes from clustering all β-catenin heavy atoms. ...............148 
4.6 Comparison of Probe changes from clustering hot region 1 heavy atoms. ...............149 
4.7 Comparison of Probe changes from clustering hot region 2 heavy atoms. ...............150 
4.8 Comparison of Probe changes from clustering hot region 3 heavy atoms. ...............151 
4.9 Comparison of Probe changes from clustering the W504 site heavy atoms..............152 
4.10 FP assay results of β-catenin point mutants. ............................................................154 
5.1 Potential substitutions based on available starting materials .....................................154 
5.2 Synthetic schemes 5-8................................................................................................173 
5.3 Predicted binding modes of proposed compounds. ...................................................175 






LIST OF TABLES 
 
Tables 
2.1 New compound results. ................................................................................................56 
3.1 HTVS success in discovering small-molecule inhibitors for PPIs. .............................98 
3.2 Results of the docking study for PPI inhibitors. ........................................................112 
4S.1 Full list of ET scores. ...............................................................................................163 
 
  
LIST OF ABBREVIATIONS 
 
Abbreviations 
APC: adenomatous polyposis coli 
AR: androgen receptor 
Arf1: adenosine diphosphate ribosylation factor 
ARNO: cytohesin-2 
BAR-1: β-catenin/armadillo-related protein 1 
BCL9: B-cell lymphoma 9 
BIR3: baculovirus inhibitor of apoptosis protein repeat 3 
BRD4: bromodomain-containing protein 4 
BRG1: Brahma-related gene 1 
C-Abl: Abelson murine leukemia viral oncogene homolog 1 kinase 
CBP: CREB-binding protein 
cDNA: complimentary DNA 
CT:  threshold cycle 
DCC: dynamic combinatorial chemistry 
DNA: deoxyribonucleic acid 
DTT: dithiothreitol 
ET: evolutionary trace 




FP: fluorescence polarization 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GPCR: G-protein coupled receptor 
GSK3: glycogen synthase kinase 3 
HPrK: histidine-containing phosphocarrier protein kinase/phosphatase 
HPRT: hypoxanthine phosphoribosyltransferase 1 gene 
HTVS: high-throughput virtual screening 
HMP-2: humpback 2 
IC50: half maximal inhibitory concentration 
IN-LEDGF: lens epithelium-derived growth factor 
IFN: interferon 
IFNAR: interferon alpha/beta receptor 1 
INT1: integrator complex subunit 1 gene 
JUP: plakoglobin 
Kd: dissociation constant 
Ki: inhibitory constant 
LE: ligand efficiency 
LEF1: lymphoid enhancer-binding factor 1 
logp: octanol/water partition coefficient 
LRP: lipoprotein receptor-related protein 
Md2: lymphocyte antigen 96 
MDM2: murine double minute 2 homolog protein 




MM/GBSA: molecule mechanics/meneralized Borne solvent accessible 
MS: mass spectroscopy 
MLL: mixed lineage leukemia protein 
MSA: multiple sequence alignment 
NEF: negative regulatory factor protein 
Ni-NTA: nickel-nitrilotriacetic acid 
NMR: nuclear magnetic resonance spectroscopy 
PAIN: Pan-assay interference 
PPI: protein–protein interaction 
Pygo: pygopus protein 
q-AP-MS: quantitative affinity pulldown mass spectroscopy 
Rac1: ras-related C3 botulinum toxin substrate 1 
rmsd: root-mean-square deviation 
RT-qPCR: quantative reverse transcriptase real-time polymerase chain reaction 
rvET: real-value evolutionary trace 
SAR: structure–activity relationship 
SCA: statistical coupling analysis 
SP: standard precision 
SYS-1: symmetrical sister cell hermaphrodite gonad defect 1 
Tiam1: T-lymphoma invasion and metastasis-inducing protein 1 
Tcf4: T-cell factor 4 
TLR4: toll-like receptor 4 





WDR5: tryptophan-aspartic acid repeat protein 5 
XIAP: X-linked inhibitor of apoptosis protein 




 I would like to acknowledge my advisor Dr. Haitao Ji for his continued support, 
and his wife Dr. Min Zhang for her efforts in the biological testing presented herein. Her 
hard work was essential for making the work presented in the second and fourth chapters 
a success. I would also like to acknowledge all members of the Ji group who have made 
themselves available to help when asked. My wife, too, deserves special thanks for loving 
me during my graduate studies, as well as aiding in the creation of the first and final images 







1.1 Protein–protein interactions as drug targets 
Protein–protein interactions (PPIs) form the cornerstone of many important 
cellular processes such as signaling pathways, cellular adhesion networks, and gene 
transcription.1 The disruption or dysregulation of PPI networks is responsible for many 
diseases.1 Therefore, PPIs make for desirable therapeutic targets. Despite composing a 
large portion of the human proteome,2,3 disproportionately few PPI inhibitors have 
advanced through clinical trials.1,3 Therefore, there is a great need to improve methods to 
discover PPI inhibitors.1 
PPIs are distinct from enzymes and other traditional drug targets including G-
protein coupled receptors (GPCRs), proteases, and kinases; these distinctions lead to 
challenges in inhibitor design.1,4 PPIs occur between two proteins over a large contacting 
surface upwards of 3,000 Å2,1 whereas enzymes have active site surfaces of less than 
1,000 Å2 .1 Key interacting residues of PPIs are dispersed throughout the larger surface, 
instead of clustered together in an active site.1 The enzyme active site has a native small-
molecule substrate which can be a template for an inhibitor, but PPIs have no such small-
molecule substrate.1 The enzyme active site is often deeply buried in the protein surface, 





low ligand efficiency (LE),2,4,5 poor pharmacokinetic properties6 and the presence of pan-
assay interference (PAIN) substructures.4,7 
The large surfaces of the PPI interface result in higher molecular weight inhibitors 
than inhibitors of traditional targets with similar potency.1 Because much of the PPI 
interaction surface is hydrophobic, small-molecule inhibitors of PPIs tend to be more 
hydrophobic.1 This hydrophobicity creates high octanol/water partition coefficient (logp) 
values.1 These characteristics create challenges when designing inhibitors with desirable 
absorptions, distribution, metabolism, and excretion pharmacokinetic properties.1 The 
presence of PAIN substructures lead to false positive hits, potential reactivity, poor 
bioavailability or toxicity.7 PPIs also face challenges with inhibitor selectivity. A single 
PPI site may accommodate multiple binding partners. Such is the case with β-catenin, 
which uses the same binding surface to interact with five different proteins.8-12 These 
challenges have led to specific strategies being developed to discover drug-like PPI 
inhibitors. 
Many of the same techniques used for drug discovery in traditional targets may be 
used to discover PPI inhibitors.1 However, specific accommodations must be made for 
differences between the deep enzyme active site and the large, shallow PPI surface. For 
example, many enzyme inhibitors have been designed from the native binding ligand of 
the enzyme. This is not possible with PPIs, but it is possible to create a small molecule 
that mimics a protein binding partner. Such molecules, known as peptidomimetic, include 
cyclic petides13 and stapled α-helices.14 However, many peptidomimetic inhibitors lack 
good drug-like properties.6 Designing drug-like small-molecule PPI inhibitors is possible, 





partner. One successful technique for inhibitor design is the use of hot spots and hot 
regions.15–17  
Certain residues, known as hot spots, contribute significantly more binding energy 
(≥ 1.5 kcal mol-1) to the binding interaction than surrounding residues.15 These residues 
are often found in deeper pockets on the protein surface.15–17 The pockets are surrounded 
by hydrophobic residues, which decrease the enthalpic penalty of the binding partner.18,19 
Areas on the PPI interface containing multiple hot spots are dubbed hot regions.18,19 The 
number of hot regions on a PPI surfaces varies from protein to protein. Hot spots and hot 
regions provide a means to effectively shrink the amount of surface that a small molecule 
needs to cover in order to inhibit a PPI.  Therefore, effectively using hot regions is 
essential to designing successful PPI inhibitors. 
 Because of poor site druggability and overlapping binding partners, directly 
targeting the binding site, known as the orthosteric site, may not be the best option. In 
this case, it may be possible to use another site on the surface of the protein to modulate 
the PPI.20 This other site is known as an allosteric site. An allosteric site is one where the 
binding of a protein or small molecule affects binding at a second site. The exact 
mechanism of allostery differs between different proteins.21–24 Several computational 
programs are able to predict potential allostery with good success. These are Statistical 
Coupling Analysis (SCA)25 and Evolutionary Trace analysis (ET).26 SCA was developed 
by the Ranganathan lab to determine energetically linked residues within proteins. A 
recent example of allostery discovered by SCA is the discovery of potential allosteric 
regulation in the dihydrofolate reductase enzyme, where no previously known allostery 





allosteric signal is conveyed, such as in kinesin.28 ET, developed by the Lichtarge lab, 
achieved similar success at discovering latent allostery. However, the method for 
determining potentially allosteric sites is based on evolutionary conservation.26 These 
scores correlate to the potential functional importance of the residue. Regions of 
potentially important residues on the surface of a protein with no known function may 
indicate latent allosteric regulation. This was recently shown with the discovery of 
allostery in dopamine receptor 2 using ET.29 Regardless if an inhibitor is of an orthosteric 
or allosteric nature, it still faces the problems associated with the PPI surface. The 
following chapters focus on a specific example, β-catenin, that exemplifies the challenges 
associated with PPI inhibitor development.  
 
1.2. The β-catenin/T-cell factor 4 interaction and the 
 Wnt signaling pathway 
β-catenin is an excellent example of a protein involved in PPI networks associated 
with disease.8,30  β-catenin has roles in the androgen receptor (AR) ligand-dependent 
transcription pathway,31 adherin cell adhesion network,32 and the canonical 
Wingless/Integration complex subunit 1 (Wnt) signaling pathway (Figure 1.1).30 β-
catenin interacts with AR to increase ligand-dependent AR activity in prostate cancer 
cells.31 The interactions between β-catenin, E-cadherin, and α-catenin are critical to link 
the extracellular components of a tight junction to the intracellular actin matrix.32 In the 
canonical Wnt signaling pathway, β-catenin interacts with axin, adenomatous polyposis 
coli (APC), and T-cell factor 4 (Tcf4) proteins.30 The β-catenin/APC and β-catenin/axin 







Figure 1.1. β-catenin is involved in multiple cellular pathways. In the canonical Wnt 
signaling pathway, β-catenin regulates transcription of Wnt target genes.30 An excess of 
β-catenin can act as a co-activator of the androgen receptor in a ligand-dependent 
manner.31 β-catenin is also a critical part of adherens junctions, acting as a link between 
cadherins and α-catenin.32 Figure derived from work described by Clevers et al31 and 





inside the nucleus, β-catenin displaces Groucho from Tcf4 to form a transcription  
complex.33 Other proteins in the transcription complex that directly interact with β-
catenin include B-cell lymphoma-9 (BCL9),30,35 CREB-binding protein (CBP),36 
Brahma-related gene 1 (BRG1),37 and pygopus (pygo).38 This transcription complex is 
responsible for promoting the transcription of Wnt target genes such as c-myc,39 cyclin 
D1,40,41 and survivin.42 The dysregulation of Wnt signaling has been implicated in a 
variety of cancers, fibroses, and neurological disorders.30 
The canonical Wnt signaling pathway was first discovered as a cell polarity 
pathway in Drosophila,43 and it was later determined to be involved in oncogenesis with 
the discovery of the highly conserved integration complex subunit 1 gene (INT1).44 The 
Wnt signaling pathway begins when a Wnt effector protein binds the extra-cellular 
domains of Frizzled (Fz)45 and lipoprotein-related receptor (LRP).46 Axin is then 
sequestered away from the destruction complex by LRP, and the kinase ability of the 
destruction complex is ablated. This leaves excess cytosolic β-catenin free to be imported 
into the nucleus and form the transcription complex responsible for transcribing Wnt 
target genes.30 In the absence of the Wnt effector protein, axin is phosphorylated and 
sequesters β-catenin in the destruction complex.47 In the destruction complex, β-catenin is 
phosphorylated by glycogen synthase kinase 3 (GSK3), and is ultimately ubiquitinated 
and degraded by the proteasome.30,48,49 Problems occur when the Wnt signaling pathway 
becomes activated without the presence of the Wnt effector protein. 
  The aberrant activation, or dysregulation, of the Wnt signaling pathway is often 
the result of genetic mutations affecting the various components of the pathway.30 





are commonly found in colon cancers and disrupt function of the destruction complex. 
Mutations of β-catenin itself can also result in oncogenesis.54 These mutations are found 
in the intrinsically disordered N-terminal tail where β-catenin is phosphorylated by 
GSK3.48,49 The lack of phosphorylation prevents β-catenin from being degraded by the 
proteasome. Under these conditions, β-catenin accumulates in the cytosol and is imported 
into the nucleus. Regardless of the source, all of these mutations lead to the untimely 
formation of the β-catenin/Tcf4 transcription complex and transcription of Wnt target 
genes. Because the β-catenin/Tcf4 PPI is the most downstream component of the Wnt 
signaling pathway before transcription, targeting this PPI poses lower risk than disrupting 
the upstream Wnt signaling pathway. This makes the β-catenin/Tcf4 PPI a prime 
therapeutic target.   
Unfortunately, the binding mode of APC, E-cadherin, and Tcf4 are highly 
overlapped and shown in Figure 1.2A.52 This presents a significant challenge for the 
development of a selective inhibitor of the β-catenin/Tcf4 PPI. The β-catenin/Tcf4 PPI 
has a dissociation constant (Kd) of 7 nM.
55 This is lower than the β-catenin/APC and β-
catenin/E-cadherin PPIs, which have Kd values of 0.6 µM and 41 nM, respectively.
55-57 
Any benefit of disrupting the β-catenin/Tcf4 interaction would be rendered moot by the 
disruption of the β-catenin/APC interaction critical to the formation of the destruction 
complex.58 The disruption of the β-catenin/E-cadherin interaction would interfere with 
cell adhesion and could result in tumor metastasis.58 Therefore, any inhibitor designed to 
inhibit the β-catenin/Tcf4 PPI must be selective. 
This may be accomplished by targeting specific β-catenin hot regions. The 







Figure 1.2. (A) Axin, APC, Tcf, and E-cadherin bind to a long groove on the armadillo 
repeat (ARM) domain of β-catenin.8 The binding groove has three hot regions (boxed). 
Bcl9 binds a distinct site near the N-terminal end of the ARM domain. (B) Hot region 1, 
also known as the deep cleft, contains four pockets.61 Binding partners APC (red, pdbID 
1TH1),11 Tcf (blue, pdbID 2GL7),35 and E-cadherin (not shown) have very similar 
binding modes in this hot region. Image created from superimposition of backbone atoms 





of β-catenin are intrinsically disordered. The middle domain consists of a repeating motif 
of two α-helices which form hairpin loops, known as an armadillo repeat (ARM). E-
cadherin, APC, and Tcf4, though mutually exclusive in binding, share a long, positively-
charged groove that spans the length of the ARM domain of β-catenin (Figure 1.2A).8 
Alanine scanning of the ARM domain revealed differences in the energetic contributions 
of residues to each interaction. K436A, R469A, and H470A mutants showed no 
transactivation of the Wnt-signaling pathway, while other nearby residue mutants, such 
as R457A, showed little-to-no reduction in Wnt signaling function.60 The mutants that did 
not activate Wnt-signaling were found to be defective in the β-catenin/Tcf4 interaction.60 
The study also showed K435A, R469A, and H470A had a greater effect on Tcf4 binding 
than on APC binding.60 Conversely, β-catenin mutants K345A and W383A were more 
disruptive to the β-catenin/APC interaction and less disruptive to the β-catenin/Tcf4 
interaction.60 The alanine scanning also revealed that the hot spot residues for binding 
Tcf4, APC, E-cadherin, and axin were clustered into three hot regions on the ARM 
domain of β-catenin. Hot region 1, also known as the deep cleft, is the binding site of the 
G13ANDE17 motif of Tcf4 (Figure 1.2B).
8,60 There are four main pockets in hot region 1, 
dubbed A, B, C, and D shown in Figure 1.2B.61 Pocket A contains residues K435, a hot 
spot for the β-catenin/Tcf4, β-catenin/APC, and β-catenin/E-cadherin PPIs, and H470, a 
hot spot that is very selective for the β-catenin/Tcf4 PPI.8 Pocket B is a deep hydrophobic 
pocket that is not utilized by any known binding partner. It is comprised of residues I507, 
V511, G512, L539, L535, I569, G572, and C573. Pocket C is a shallow, hydrophobic 
surface consisting of the arginine channel, R474 and R515, and the nearby hydrophobic 





A509, L539, and I569. The next hot region on the large, positively-charged groove of β-
catenin is hot region 2.8,60 The residues important for Tcf4 binding in hot region 2 include 
Y306, K312, K335, W338, R342, K345, Y354, and R376. The final hot region, hot 
region 3, includes key residues R212, R225, F253, H260, K270, R274, and R292.8,61 
Included in these hot regions are three residues, K292, K335, and R376 that interact with 
a pS/pT-motif on E-cadherin10 and APC.11,56 The phosphorylation of E-cadherin 
increases its affinity for β-catenin 1,000-fold.10 Tcf4 does not undergo phosphorylation 
and relies more on hot region 1 than hot regions 2 or 3.8 Because of the therapeutic 
importance of β-catenin, it has been the target of many drug design campaigns.57 Some of 
these have been successful while others have been stifled by the problems common to 
PPIs.   
 
1.3 Previously discovered Wnt inhibitors 
Much work has gone into the discovery of inhibitors of the β-catenin/Tcf4 PPI 
(Figure 1.3). The first β-catenin/Tcf4 inhibitors were discovered by Lepourcelet et al.62 
by a high-throughput screen. These include compounds 1 (PKF115-584), 2 
(CGP049090), and 3 (PKF118-380). These inhibitors obtained half maximal inhibitory 
concentration (IC50) values of 3.2 µM, 0.8 µM, and 8.7 µM, respectively.
62 The binding 
mode of these inhibitors was not elucidated, and subsequent testing for selectivity of 
these compounds showed little difference in their ability to inhibit the β-catenin/Tcf4 
interaction over the β-catenin/APC and β-catenin/E-cadherin interactions.61 In 2006, 4 
(PNU 74654) was discovered by Trosset, et al.63 through high-throughput screening and 
obtained a Kd of 450 nM.







Figure 1.3. Many compounds have been developed to inhibit the β-catenin/Tcf4 PPI. In 
the case of PKF115-584, PKF115-584, CGP049090, PNU 74654, iCRT3, iCRT5, and 
iCRT14, the values indicate the results of a fluorescence polarization assay by Min Zhang 
to directly measure disruption of the β-catenin/Tcf interaction.59 Adapted with permission 
from Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule 
Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 4678-4692. 





signaling pathway, 5 (iCRT3), 6 (iCRT5), and 7 (iCRT14) were discovered by 
Gonsalves, et al.64 These inhibitors were shown to disrupt the Wnt signaling pathway but 
not specifically the β-catenin/Tcf4 PPI. When assessed for the ability to inhibit the β-
catenin/Tcf4 PPI, these inhibitors had weaker inhibitory constant (Ki) values of 364 µM, 
80.3 µM, and 53.5 µM, respectively.59 More recently, Hwang et al. identified 8 (methyl 
3-{[(4-methyl-phenyl) sulfonyl]amino}benzoate) as a Wnt inhibitor with an IC50 of 530 
nM that binds to the ARM domain of β-catenin.65 Fang et al. developed 9 (LF3),66 which 
inhibits the β-catenin/Tcf4 PPI with an IC50 of 1.7 µM and does not inhibit the β-
catenin/E-cadherin PPI. 
The Ji lab achieved success at developing inhibitors for the β-catenin/Tcf4 
PPI.59,61,67 The first potent inhibitor in the lab, 10, was developed by postdoctoral fellow 
Dr. Binxun Yu.59 Compound 10 was created through bioisostere replacement using 
human Tcf4 residues E17 and D16—these residues of Tcf4 form salt bridges with β-
catenin hot spots K508 and K435, respectively.59 Compound 10 achieved a Ki of 3.14 
µM. Isothermal titration calorimetry studies using K435A, R469A, and K508A β-catenin 
mutants were used to validate the binding mode of 10.59 The results of this study 
indicated that 10 bound hot region 1. Next, Dr. Zheng Huang developed a 
peptidomimetic inhibitor 11 (UUT-02).61 This compound was effective at inhibiting the 
β-catenin/Tcf4 PPI by mimicking the G13ANDE17 portion of Tcf4. Compound 11 marks a 
significant milestone in the development of β-catenin/Tcf4 PPI inhibitors. It is the first 
inhibitor to achieve selectivity for the β-catenin/Tcf4 PPI over the β-catenin/APC and β-
catenin/E-cadherin PPIs.61 The success of 11 puts hot region 1 in the spotlight as the 





Herein, some of the commonly encountered problems of PPI inhibitor design are 
tackled. First, common challenges associated with small-molecule inhibitor design are 
addressed through the optimization of 12 (UZI/7116003).67 Compound 12 was identified 
by Dr. Min Zhang as an inhibitor of the β-catenin/Tcf4 PPI, but this small molecule 
contained the acyl hydrazone PAIN substructure.67 From this inhibitor, a new scaffold, 
13, was developed by Dr. Yongqiang Zhang and optimized to interact with β-catenin hot 
spot K435, resulting in 14.67 This new series of inhibitors were specific for the β-
catenin/Tcf4 PPI over the β-catenin/E-cadherin and β-catenin/APC PPIs, and showed 
Wnt inhibitory activity both in vitro and in vivo.67 
Furthermore, the abilities of common high-throughput virtual screening (HTVS) 
programs to identify potent PPI inhibitors are examined. Past discovery of PPI inhibitors 
by HTVS has proved challenging, and it has been noted that current software may be ill-
suited for HTVS of PPIs.2 Herein, the effects of different docking algorithms and scoring 
functions were assessed for PPIs, and it was found that neither program proved better at 
handling HTVS of PPI inhibitors. In order to enhance the HTVS results, a physics-based 
re-ranking based on molecular mechanics/generalized Borne solvent accessible 
(MM/GBSA) binding energy calculations. The effect of ligand burial2 on inhibitor 
potency was also examined, and a weak, but significant, correlation was observed, 
indicating that a more buried inhibitor was more potent.  
Lastly, ET analysis, solvent mapping and molecular dynamic (MD) simulations 
were applied to β-catenin to explore ligand selectivity and identify a novel allosteric site. 
Solvent mapping analysis of different β-catenin crystal structures with binding partners 





axin rely comparatively more on hot regions 2 and 3. ET sequence analysis was used to 
discover a novel, potentially allosteric region on the surface of β-catenin. This site does 
not interact with Tcf4, APC, or E-cadherin, and the disruption of this site increases β-
catenin/Tcf4 binding. The discovery of this site will prove useful for small-molecule 
allosteric regulation of the β-catenin/Tcf4 PPI. 
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Authors Note: This chapter contains material originally published from a collaboration 
of Jonathan Leon Catrow, Dr. Yongiang Zhang, and Dr. Min Zhang. The text has been 
rewritten and reorganized to include further work performed on this series of inhibitors. 
Figures 2.1–2.11 are adapted with permission from the original manuscript.  
 
2.1 Introduction 
The canonical Wnt signaling pathway is critical for regulating cell growth, 




commonly found in cancer stem cells, which are resistant to traditional therapies.3-5 
Mutations in axin, APC, and β-catenin, which represent the key regulatory components of 
the Wnt signaling pathway, result in the untimely expression of Wnt target genes 
including c-myc,6 cyclin D1,7 and survinin.8 The penultimate step of the Wnt signaling 
pathway is the formation of a transcription complex initiated by the β-catenin/Tcf4 PPI.1 
Therefore, the β-catenin/Tcf4 PPI is an appealing target to inhibit the canonical Wnt 
signaling pathway.9 
The crystal structure of β-catenin in complex with human Tcf4 (PDB ID 2GL7)10 
shows that the interacting surface between β-catenin and Tcf4 is approximately 3,500 Å2, 
while most PPI surfaces are between 1,200-2,500 Å2.11 The crystallographic binding 
mode of human Tcf4 reveals that most interactions with β-catenin occur in three hot 
regions on the β-catenin ARM domain.10,12-18 Hot region 1 contains β-catenin hot spots 
K435 and K508, which form charge-charge interactions with human Tcf4 residues D16 
and E17, respectively. Disruption of the Tcf4 D16/β-catenin K435 interaction reduced the 
β-catenin/Tcf4 interaction by 1000-fold.14,18 Previous surface plasmon resonance (SPR) 
studies indicated that these two interactions in hot region 1 were more important than 
interactions in other hot regions.16 In hot region 2, β-catenin K312 and K345 form 
charge-charge interactions with Tcf4 E24 and E29, respectively.10-13 Hot region 3 
contains the hydrophobic interactions of Tcf4 V44 and L48 with β-catenin F253, I256, 
F293, A295, and A296.19 In addition to Tcfs, these hot regions also bind E-cadherin 
(human E-cadherin residues 819-876, PDB ID 1I7X)20 and the third 20 amino acid repeat 
of APC (human APC residues 1477-1519, PDB ID 1TH1),21 and axin (human axin 




of these proteins indicated that Tcf4, E-cadherin, and APC interacted with all three hot 
regions, while axin only interacted with hot region 3.22 The β-catenin/APC and 
β-catenin/axin interactions are crucial for regulating β-catenin degradation through the 
destruction complex.19,21 The β-catenin/E-cadherin interaction is a component of cell-cell 
adhesion, and the disruption of this PPI could disrupt adhesion and result in tumor 
metastasis.20 Therefore, it is critical that an inhibitor that binds β-catenin be selective for 
the β-catenin/Tcf4 PPI over the β-catenin/E-cadherin and β-catenin/APC PPIs. The β-
catenin/Tcf4 interaction is the strongest of the three binding partners (Kd = 7 nM),
15,23,24 
while the β-catenin/E-cadherin (Kd = 41 nM)23,25,26 and β-catenin/APC (Kd = 0.6 
μM)21,23,25,27,28 are weaker. The tight interaction between β-catenin/Tcf4 complicates 
inhibitor design.  
Several successful β-catenin/Tcf4 inhibitors have been reported, most of which 
were not found to be selective (Figure 2.1).29 A high-throughput screening identified six 
natural products out of 52,000 compounds, 1, 2, 3, 15 (PKF118-744), 16 (ZTM000990), 
and 17 (PKF222-815) as inhibitors of the β-catenin/Tcf4 PPI.29 Despite achieving good 
potency, compounds 1, 3, 15, and 16 contain quinine-like PAIN substructure,30 while 2 
contains the toxoflavin PAIN substructure.30,31 These PAIN substructures are associated 
with a high rate of false-positive hits and toxicity.32 Compound 4 was identified through 
virtual and biophysical screening and contained the acyl hydrazone PAIN substructure.30 
No further study or optimization was reported. The iCRT series of inhibitors, 5, 6, and 7, 
disrupted axin knockdown-induced Wnt signaling, downregulated Wnt target genes, and 
inhibited the growth of colorectal cancer cells.33 However, 5 was reported to undesirably 






Figure 2.1. Previous β-catenin/Tcf4 PPI inhibitors. Compounds 1, 2, 15, and 16 contain 
quinine-like PAIN substructure.30 Compound 3 contains the toxoflavin PAIN 
substructure. Compound 4 contains the acyl hydrazone PAIN substructure. Compounds 6 
and 7 contain a rhodanine-like PAIN substructure. Adapted with permission from 
Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule 
Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 4678-4692. 





in 6 and 7, which may lead to nonspecific binding and off-target effects.30,35,36 A virtual 
screen of the Tcf4 D16ELISF21 binding site on β-catenin found that 18 (BC21) was a 
potent inhibitor of the β-catenin/Tcf4 interaction with cell-based activity,37 but no further 
study of the selectivity of 18 has been reported. Compound 19 (aStAx-35) is a stapled α-
helix peptidomimetic compound based on axin residues S471-V480 and was designed to 
inhibit the β-catenin/Tcf4 interaction by binding hot region 3.38 However, it may also 
disrupt the β-catenin/axin PPI, which is responsible for regulating the degradation of β-
catenin through the destruction complex.19,39 Compound 10 (UUT-01) was developed by 
postdoctoral fellow Dr. Binxun Yu to mimic the binding mode of Tcf4 D16 and E17 to β-
catenin K435 and K508, respectively.16 Using the Tcf4 G13ANDE17 structure as a guide, 
Dr. Zheng Huang developed a peptidomimetic inhibitor, 11 (UUT-02), of the β-
catenin/Tcf4 PPI.39 This compound was not only a potent β-catenin/Tcf4 inhibitor, but it 
was selective for the β-catenin/Tcf4 PPI over the β-catenin/E-cadherin and β-
catenin/APC PPIs.39 As such, 11 served as a proof of concept that the G13ANDE17 
binding site of hot region 1 could be used for selective inhibition of the β-catenin/Tcf4 
PPI.39 
This chapter presents an evaluation and optimization of 12, a β-catenin/Tcf4 
inhibitor shown to bind the hot region 1 of β-catenin. Compound 12, which was 
discovered by high-throughput screening, inhibited the β-catenin/Tcf4 interaction, 
disrupted transactivation of the Wnt signaling pathway and inhibited cancer cell growth. 
However, this compound contained the acyl hydrazone PAIN substructure.30 Despite 
problems reported with the acyl hydrazone structure, it is highly represented in reported 




substructure resulted in 11,490 publications between 1993 and 2014 (Figure 2.2). The 
acyl hydrazone moiety is an important component in dynamic combinatorial chemistry 
(DCC).40-42 The formation of the acyl hydrazone substructure is important for DCC 
because it is reversible, yet it is stable under physiological pH.42 DCC studies using the 
formation of the acyl hydrazone moiety resulted in inhibitors of acetylcholinesterase,43 
aspartic proteases,44 β-tryptase,45 and Bacillus subtilis histidine-containing 
phosphocarrier protein kinase/phosphatase (HPrK).46 The acyl hydrazone substructure is 
also present in two FDA approved drugs, the antibiotic nitrofurantoin and the calcium 
sensitizer levosimendan. Therefore, a need exists to better understand the biological 
activities of acyl hydrazone-containing inhibitors as well as to develop efficient means of 
PAIN substructure removal and optimization of acyl hydrazone-containing compounds. 
 
2.2 Methods 
 2.2.1. Protein expression and purification.  Wild-type (WT) or mutant β-catenin 
complimentary DNA (cDNA) was cloned into either a Novagen pET28b vector or a 
pEHISTEV vector (provided by Dr. Hanting Liu of St. Andrew University, UK) resulting 
in a C-terminal 6X-His tag or N-terminal 6X-His tag fusion, respectively. Plasmids were 
transformed into Novagen BL21 DE E. coli cells and cultured in LB media containing 30 
μg/mL kanamycin at 37 °C until the OD600 reached approximately 0.8. At this time, β-
catenin expression was induced by 400 μM of isopropyl β-D-1-thiogalactopyranoside 
(IPTG). Proteins were expressed at 20 °C overnight. To extract proteins, cells were 
sonically lysed, and the protein was purified using nickel-nitriloaceticacid (Ni-NTA) 






Figure 2.2. Publications involving biological activities of the acyl hydrazone moiety. 
Results of a SciFinder search result for the publications that include the biological 
activities of the acyl hydrazone sructure between 1993–2014. Adapted with permission 
from Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule 
Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 4678-4692. 




of 20 mM Tris, 100 mM NaCl, 10% glycerol, and 3 mM dithiothreitol (DTT) at pH 8.8 
overnight at 4 °C. β-catenin was isolated at 95% purity as determined by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. A thermal shift assay 
to evaluate protein stability, unfolding, and aggregation was performed using a BioRad 
iCycler iQ real-time detection system, Sypro Orange dye, and a temperature gradient of 1 
°C/min. Circular dichroism (CD) spectroscopy was used to evaluate mutant protein 
folding. A Jasco J-85 spectropolarimeter was used to record CD spectra with a 1 mm 
path-length quartz cell at room temperature (rt). CD spectra scans were conducted from 
90 nm to 260 nm in 1 nm increments. Three CD spectra scans were averaged together. 
Spectra were base-line corrected using a blank sample containing everything except 
protein. Samples of 1–5 μM protein were prepared in a buffer of 10 mM potassium 
phosphate and 100 mM potassium fluoride and adjusted to pH 7. Protein was stored in 
100 μL aliquots at -80 °C. High performance liquid chromatography (HPLC) purified (> 
95% purity) C-terminally biotinylated human Tcf4 (residues 7-51), C-terminally 
fluorescein-labeled human Tcf4 (residues 7-51), C-terminally fluoroscein-labeled human 
E-cadherin (residues 819-873) and C-terminally fluoroscein-labeled human APC 
(residues 1477-1519) were synthesized by InnoPep, Inc. The synthesized peptide 
structures were validated using liquid chromatography/mass spectrometry. 
 2.2.1 Fluorescence polarization (FP) and AlphaScreen assays.  10 mM stock 
solutions in DMSO were prepared for all screened compounds. For the initial screen, all 
compounds were tested at a 50 μM concentration in 1% (v/v) DMSO solution. 
Compounds achieving > 50% reduction of signal in both the FP assay and AlphaScreen 




passed the counter screen were further evaluated through a second round of the FP and 
AlphaScreen assays to establish a dose-dependent response. For the FP assay, an assay 
buffer of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 1% (v/v) 
DMSO, 100 μg/mL bovine γ-globin, and 0.01% (v/v) Trition-X100 was used to reduce 
aggregation. 10 nM β-catenin and 2.5 nM fluoroscein-labeled Tcf4 were incubated in the 
assay buffer for 15 min at 4 °C. A range of concentrations of the test compound were 
tested in the assay buffer in a 96-well plate at a final well volume of 100 μL. The reaction 
was allowed to equilibrate while gently shaking on an orbital mixer in the dark for 1.5 h 
at 4 °C before polarization values were recorded. IC50 values were calculated using a 
nonlinear least-squares analysis with GraphPad Prism 5.0 and Ki values were derived 
from the IC50. All samples were tested in triplicate.  
A buffer of 20 mM HEPES, 100 mM NaCl, 0.1% BSA, and 0.001% Triton-X100 
was used for AlphaScreen testing. Five nM of C-terminally biotinylated Tcf4 and 20 nM 
of N-terminally 6X His-tagged β-catenin were incubated in buffer for 45 min. A range of 
concentrations of the test compound were tested in the assay buffer in a 384-well plate at 
a final volume of 100 μL. The reaction was allowed to equilibrate while gently shaking 
on an orbital mixer in the dark for 2 h at 4 °C before emission values were recorded. IC50 
and Ki values were determined in the same manner as the FP assay. All samples were 
tested in triplicate. 
 2.2.3 Cell viability assay.  Wnt-active colorectal cancer cell lines SW480, HT29, 
and HCT116, as well as HEK293 cells were seeded in 96-well plates at a density of 4000 
cells/well and incubated overnight at 37 °C. A range of test compound concentrations 




incubated for 3 h in 10 μL of a fresh solution of 1:19 phenazine methosulfate (PMS, 
Sigma) solution (0.92 mg/mL) and 3-4,5-dimethylthiazol-2-yl)-5-3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-terazolium (MTS, Promega). The effect 
of the tested compounds was measured using A490 and IC50 values were calculated. All 
compounds were tested in triplicate. 
 2.2.4 Cell transfection and TOPFlash luciferase reporter gene assay.  FuGENE 6 
(E2962, Promega) was used to transfect HEK293 and SW480 cells in a 96-well plate per 
manufacturer’s instructions. HEK293 cells were cotransfected with 45 ng of either 
TOPFlash or FOPFlash reporter gene and 40 ng of pCMV-RL reporter for normalization 
and 135 ng of pcDNA3.1-β-catenin. SW480 cells were cotransfected with 60 ng of either 
TOPFlash or FOPFlash reporter gene and 40 ng of pCMV-RL reporter for normalization. 
Cells were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% of 
fetal bovine serum at 37 °C for 24 h. After 24 h, varying concentrations of inhibitors 
were added and the cells incubated for another 24 h. Inhibitor reporter activity was 
measured using a Dual-Glo system (E2940, Promega). Luciferase activity was 
normalized to pCMV-RL reporter activity and activity was compared to cells treated with 
only DMSO. The TOPFlash reporter gene was performed in triplicate. 
 2.2.5 Quantitative reverse transcriptase real time PCR analysis (RT-qPCR).  
SW480 cells at a density of 1,000,000 cells/mL were treated with a range of 
concentrations of compounds at 37 °C for 24 h. All mRNAs were extracted using TRIzol 
(155960269, Life Technologies), and cDNA was synthesized using the Superscript III 
first-strand kit (18080-051, Invitrogen).  Quantitative real-time PCR was performed with 




real time PCR reaction system. Threshold cycle (CT) values were normalized to a human 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) internal reference gene using 
primer pairs forward 5'-GAAGGTGAAGGTCGGAGTC-3' and reverse 5'- 
GAAGATGGTGATGGGATTTC-3'. Human hypoxanthine phosphoribosyltransferase 1 
(HPRT), a house-keeping reference gene, was used as a control, with primers forward 5'-
GCTATAAATTCTTTGCTGACCTGCTG-3' and reverse 5'-
AATTACTTTTATGTCCCCTGTTGACTGG-3'. Axin2, cyclin D-1 and c-myc cDNA 
levels were monitored for Wnt target gene expression; Axin2 forward 5'-
AGTGTGAGGTCCACGGAAAC-3', and reverse 5’-CTTCACACTGCGATGCATTT-
3'; cyclin D-1 forward 5'-ACAAACAGATCATCCGCAAACAC-3’, and reverse 5'-
TGTTGGGGCTCCTCAGGTTC-3'; c-myc forward 5'-
CTTCTCTCCGTCCTCGGATTCT-3', and reverse 5'-
GAAGGTGATCCAGACTCTGACCTT-3'. Compounds were tested in triplicate.  
 2.2.6 Western blotting.  SW480 colorectal cancer cells at a density of 1,000,000 
cells/mL were treated with a range of concentrations of compounds and incubated at 37 
°C for 24 h. Cells were chemically lysed in a buffer of 50 mM Tris, 150 mM NaCl, 1% 
Nonidet P40, 0.5% sodium deoxycholate, 1% SDS, and protease inhibitors at pH 7.4.  
The supernatant was collected after 20 min of centrifugation at 12,000 rpm and 4 °C and 
loaded onto an 8% SDS-PAGE for separation. Separated proteins were transferred onto a 
nitrocellulose membrane for immunoblot assays. Primary antibodies against c-myc 
(D84C12, Cell Signaling), cyclin D1 (sc-853, Santa Cruz Biotechnology, Inc), and β-
tubulin, a control (sc-55529, Santa Cruz Biotechnology, Inc.), proteins were used. The 




or IRDye 800CW goat antirabbit IgG (827-08365, LiCOR). Western blot bands were 
detected using LiCOR Odyssey infrared imaging system and quantified using LiCOR 
Image Studio Lite 4.0 software. Compounds were tested in duplicate. 
 2.2.8 Coimmunoprecipitation assay.  SW480 colorectal cancer cells at a density 
of 1,000,000 cells/mL were treated with a range of concentrations of 12 and incubated at 
37 °C for 24 h. Cells were chemically lysed in a buffer of 50 mM Tris, 150 mM NaCl, 
1% Nonidet P-40, 2 mM EDTA, and protease inhibitors at pH 7.4. The resulting lysates 
were preadsorbed onto A/G plus agarose (sc-2003, Santa Cruz Biotechnology, Inc) for 1 
h at 4 °C. A/G plus agarose was then added and the mixture incubated for 3 h at 4 °C. 
The beads were washed 5 times with the same buffer used for cell lysis at 4 °C. Bound 
proteins were eluted by boiling the beads in SDS sample buffer. Eluted proteins were 
then loaded onto SDS-PAGE for separation. The separated proteins were transferred onto 
nitrocellulose membranes for Western blot analysis. Primary antibodies against β-catenin 
(610153, BD Biosciences) and human Tcf4 (05-511, Millipore) and secondary antibodies 
IRDye 680LT goat antimouse IgG (827-11080, LiCOR) were used. Images were 
captured using the LiCOR infrared imaging system. Compound 12 was tested in 
duplicate. 
 2.2.9 Ligand docking using AutoDock Vina.  A blind docking of 12 was 
performed using AutoDock Vina.47 Overlapping grids were generated to cover the entire 
β-catenin (PDB ID 2GL7)10 surface. Exhaustiveness was increased to 12 (exhaustiveness 
= 12), and 18 ligand conformations were generated for each grid (num_modes = 18). All 
other parameters were left as default values. Compound 49 was docked into a grid 




 2.2.10 Ligand docking using Glide 5.8.  All ligand structures were prepared by 
Schrodinger LigPrep48 using Epik49 to generate protonation and tautomeric states at pH 
7.0. Ligand structures were minimized using the OPLS_2005 force field50 in generalized 
Born solvent accessible (GBSA) implicit water solvent conditions. Atomic partial 
charges were assigned by the OPLS_2005 force field. A grid encompassing all residues 
of the human Tcf4 G13ANDE17 binding region of β-catenin was generated with default 
Glide parameters.51 The ligand scaling factor was adjusted to 0.5 for atoms with partial 
charges lower than 0.15. 10,000 poses were generated during the initial phase of docking 
and the 1,000 best poses were kept for a 5,000-step maximum energy minimization. Up 
to 100 poses per ligand were minimized post-docking. A maximum of 100,000 ligand 
poses were generated per docking run with a maximum of 50 poses reported per ligand. 
All remaining settings were kept as default for Glide standard precision.51,52  
 2.2.11 Ligand docking using AutoDock 4.2.  AutoDock Tools and AutoTors were 
used to generate united atom ligand coordinates utilizing Gasteiger-Marsili atomic partial 
charges and define torsion trees.53 Grids covering all residues of the human Tcf4 
G13ANDE17 binding region of β-catenin were generated with AutoGrid 4 with 0.375 Å  
grid spacing. Ligands were docked using 100 iterations of a Lamarckian genetic 
algorithm to generate 100 poses per ligand.53  
2.2.12 Compound sources, general chemical methods, reagents, and materials for 
chemical synthesis.  Compounds 20-23 and 27-30 were purchased from Sigma-Aldrich. 
Compounds 12 (UZI/7116003) and 26 (UZI/2587998) were purchased from the Zelinsky 
Institute, Inc. (Newark, Delaware, USA). Compound 12 was resynthesized by Dr. 




InterBioScreen (Moscow, Russia). Compounds 8 and 9 were resynthesized by the Ji lab 
(University of Utah, Salt Lake City, Utah, USA). Chemical reagents were purchased from 
Sigma-Aldrich, Acros Organics, or Ark Pharm, Inc. and used as is without further 
purification unless otherwise stated. 1H and 13C NMR spectra were recorded using a 
Varian VXR-500 (500 MHz, 125.7 MHz 13C), Varian Inova-400 (400 MHz 1H, 100 MHz 
13C) or Varian Unity-300 (300 MHz 1H, 75 13C) spectrometers (Figures 2S.1 – 2S.20). 
Chemical shifts were reported as parts per million. 1H reference peaks were set at 7.26 
ppm, 2.5 ppm and 2.05 ppm for CHCl3, (CD2H)2SO, and (CD2H)2CO. 
13C reference 
peaks were set at 77.23 ppm, 39.52 ppm, and 29.84 ppm for CDCl3, DMSO-d6, and 
acetone-d6. Low- and high- resolution mass spectra were obtained using a Μmass Quattro 
II mass spectrometer with an ESI source. Thin-layer chromatography was conducted with 
E. Merck precoated silica gel 60 F254 plates with visualization accomplished with a UV-
visible lamp. Column chromatography was performed using 234-400 mesh SilaFlash 
F60.  
 2.2.13 Chemical synthesis.  All synthesized compounds except for 34-40 and 44-
49 were synthesized by Dr. Yongqiang Zhang. Compounds 45, 47, and 49 were 
synthesized by undergraduate ACCESS fellow Brooklyn Brakey.  
9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-one (24). 1,2,5-oxadiazole-
3,4-diamine (0.18 g, 1.80 mmol) was added to a solution of ninhydrin (0.32 g, 1.80 
mmol) in a solvent mixture of ethanol and glacial acetic acid (1:1, 10 mL). After stirring 
for 18 h at rt, the mixture was heated to a gentle reflux for another 6 h. It was then cooled 
to rt, and the resulting precipitate was filtered and washed with water to yield 24 as a pale 




Hz, 1H), 8.18–8.02 (m, 2H), 7.97 (d, J = 7.2 Hz, 1H). 13C NMR (125 MHz, DMSO-d6) δ 
ppm 189.6, 161.7, 140.0, 140.0, 138.7, 136.5, 126.1. HRMS (ESI) calcd for C11H4N4O2 
(M + Na)+ 247.0232, found 247.0230. 
(Z)-9-Hydrazono-9H-indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazine (25). 
Hydrazine hydrate (0.33 g, 6.70 mmol) was added to a solution of 24 (0.15 g, 0.67 mmol) 
in a mixture of ethanol and glacial acid (1:1, 10 mL). The mixture was heated to a gentle 
reflux for 2 h and then cooled to rt. The resulting precipitate was filtered and washed with 
water to afford 24 as a red solid (0.14 g, 93% yield). 1H NMR (300 MHz, DMSO-d6) δ 
ppm 10.48 (d, J = 13.8 Hz, 1H), 10.40 (d, J = 13.8 Hz, 1H), 8.07 (d, J = 7.5 Hz, 1H), 
7.73–7.66 (m, 2H), 7.46 (t, J = 7.5 Hz, 1H). 13C NMR (75 MHz, DMSO-d6) δ ppm 161.8, 
155.0, 152.7 152.5, 144.8, 135.9, 129.8, 128.9, 128.5, 124.7, 119.7. HRMS (ESI) calcd 
for C11H6N6O (M – H)− 237.0525, found 237.0531. 
4-Amino-1,2,5-oxadiazole-3-carbohydrazide (43). HCl gas was bubbled into a 
solution of 4-amino-1,2,5-oxadiazole-3-carboxylic acid (0.50 g, 3.87 mmol) in methanol 
(30 mL). The mixture was heated to a gentle reflux for 8 h. Methanol was then removed 
by vacuum to give the crude product as a pale yellow oil. Diethyl ether (30 mL) was 
added to this residue and stirred for 30 min. The resulting precipitate was filtered to give 
desired product 42 (0.50 g, 91% yield) as a white solid. It was used directly in the next 
step without further purification. Hydrazine hydrate (0.08g, 1.57 mmol) was added to a 
solution of 42 (0.15 g, 1.05 mmol) in methanol (10 mL), and the mixture was heated to a 
gentle reflux. After 15 h, the solvent was removed completely under vacuum to give 43 
(0.09 g, 60% yield) as a white solid. 1H NMR (500 MHz, acetone-d6) δ ppm 9.50 (brs, 




calcd for C3H5N5O2 (M + H)
+ 144.0516, found 144.0519. 
(Z)-4-Amino-N′-(9H-indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-ylidene)-
1,2,5-oxadiazole-3-carbohydrazide (12). Compound 43 (0.03 g, 0.22 mmol) and glacial 
acetic acid (1 mL) was added to a solution of 24 (0.05 g, 0.22 mmol) in ethanol (10 mL). 
The reaction mixture was heated to a gentle reflux overnight and then poured into ice 
water. The resulting precipitate was filtered and washed with water to give 12 as a yellow 
solid (0.06 g, 78% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 13.55 (brs, 1H), 8.26 (d, 
J = 7.5 Hz, 1H), 8.06 (d, J = 7.0 Hz, 1H), 7.92 (t, J = 7.5 Hz, 1H), 7.82 (t, J = 7.0 Hz, 
1H), 6.01 (s, 2H). 13C NMR (125 MHz, DMSO-d6) δ ppm 162.8, 158.6, 157.1, 155.4, 
153.2, 152.3, 152.0, 144.3, 140.4, 136.8, 134.6, 133.7, 125.2, 122.8. HRMS (ESI) calcd 
for C14H7N9O3 (M – H)− 348.0594, found 348.0604. 
5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indole (31). 1,2,5-oxadiazole-3,4-
diamine (0.14 g, 1.36 mmol) was added to a solution of isatin (0.20 g, 1.36 mmol) in 
glacial acetic acid (5 mL). The resulting mixture was heated to a gentle reflux for 15 h 
and then poured into ice water. The resulting precipitate was filtered and washed with 
water to afford 31 as a red solid (0.05 g, 17% yield). 1H NMR (300 MHz, DMSO-d6) δ 
ppm 12.35 (brs, 1H), 8.19 (d, J = 7.8 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.39 (d, J = 8.1 
Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H). 13C NMR (75 MHz, DMSO-d6) δ ppm 154.0, 152.6, 
152.5, 151.9, 148.8, 136.4, 125.3, 123.1, 118.9, 113.4. HRMS (ESI) calcd for C10H5N5O 
(M – H)− 210.0416, found 210.0427. 
Ethyl-2-(5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)acetate (32). 
K2CO3 (0.08 g, 0.57 mmol) was added to a solution of 31 (0.08 g, 0.38 mmol) and ethyl 




heated to 80 °C overnight. After 15 h, the reaction mixture was cooled to rt and diluted 
with ethyl acetate (80 mL), and washed with brine (20 mL × 3). The organic layer was 
dried over Na2SO4, filtered and concentrated. The residue was purified by column 
chromatography (silica gel, hexanes:acetone = 5:1) to afford 32 (0.08 g, 73% yield) as a 
red solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.28 (d, J = 7.5 Hz, 1H), 7.85 (t, J = 7.0 
Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 5.22 (s 2H), 4.18 (q, J = 7.0 
Hz, 2H), 1.21 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, DMSO-d6) δ ppm 168.0, 153.2, 
152.3, 152.1, 151.6, 148.9, 136.5, 125.3, 124.1, 118.5, 112.4, 62.3, 43.4, 14.7. HRMS 
(ESI) calcd for C14H11N5O3 (M + Na)
+ 320.0760, found 320.0759. 
2-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)acetic Acid (33). 
LiOH (0.05 g, 2.15 mmol) was added to a solution of 32 (0.08 g, 0.27 mmol) in a solvent 
mixture (14 mL, THF:MeOH:H2O = 4:2:1). The mixture was stirred for 8 h at rt. Then, 
the pH value was adjusted to 4–5 with HCl (1 M), diluted with water (50 mL) and 
extracted with ethyl acetate (20 mL × 3). The combined organic phase was dried over 
Na2SO4 and concentrated to give 33 (0.05g, 68%) as an orange solid. 
1H NMR (500 
MHz, DMSO-d6) δ ppm 13.36 (brs, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 8.0 Hz, 
1H), 7.69 (d, J = 8.0 Hz, 1H), 7.41 (t, J = 8.0 Hz, 1H), 5.10 (s, 2H). 13C NMR (125 MHz, 
DMSO-d6) δ ppm 169.4, 153.2, 153.0, 152.1, 151.6, 149.1, 136.5, 125.3, 124.0, 118.4, 
112.4, 43.4. HRMS (ESI) calcd for C12H7N5O3 (M – H)− 268.0471, found 268.0485. 
2-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)-N-(4-amino-1,2,5-
oxadiazol-3-yl)acetamide (13). Isobutyl chloroformate (0.09 g, 0.67 mmol) was added to 
a solution of 33 (0.18 g, 0.67 mmol) and 4-methylmorpholine (0.14 g, 0.34 mmol) in 




temperature. Then 1,2,5-oxadiazole-3,4-diamine (0.10 g, 1.00 mmol) was slowly added. 
The temperature was allowed to rise to rt gradually and stirred for another 1 h. The 
mixture was diluted with ethyl acetate (80 mL), and washed with brine (20 mL × 3). The 
organic layer was dried over Na2SO4, filtrated, and concentrated. The product was 
purified by column chromatography (silica gel, hexanes:acetone = 2:1 to 1:1) to afford 13 
(0.12 g, 51% yield) as an orange solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 11.13 (brs, 
1H), 8.32 (d, J = 7.5 Hz, 1H), 7.87 (t, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.45 (t, J 
= 7.5 Hz, 1H), 6.04 (s, 2H), 5.29 (s, 2H). 13C NMR (125 MHz, DMSO-d6) δ ppm 166.7, 
153.5, 152.9, 152.4, 152.1, 152.0, 149.3, 144.3, 136.5, 125.3, 124.0, 118.7, 112.6, 44.8. 
HRMS (ESI) calcd for C14H9N9O3 (M – H)− 350.0750, found 350.0755. 
Ethyl 4-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)butanoate (36). 
NaH (0.0030 g, 0.12 mmol) was added to a solution of 31 (0.017 g, 0.08 mmol) in DMF 
(5 mL) at 0 °C. The resulting mixture was stirred for 0.5 h at 0 °C before adding ethyl 4-
bromobutanoate (0.023 g, 0.12 mmol). The reaction solution was allowed to warm to rt 
gradually then stirred overnight. The mixture was diluted with ethyl acetate (50 mL), and 
washed with brine (20 mL × 3). The organic layer was dried over Na2SO4, filtrated, and 
concentrated. The product was purified through column chromatography (silica gel, 
hexanes:acetone = 3:1 to 1:1) to afford 36 as an orange solid (0.010 g, yield 58%). 1H 
NMR (400 MHz, CDCl3) δ ppm 8.20 (d, J = 7.2 Hz, 1H), 7.71 (t, J = 7.2 Hz, 1H), 7.42 
(d, J = 8.0 Hz, 1H), 7.31 (t, J = 7.2 Hz, 1H), 4.32 (t, J = 6.8 Hz, 2H), 4.07 (q, J = 6.0 Hz, 
2H), 2.43 (t, J = 6.4 Hz, 2H), 2.20–2.12 (m, 2H) 1.19 (t, J = 6.0 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ ppm 172.5, 151.8, 151.3, 151.2, 150.4, 148.0, 135.6, 125.1, 123.1, 118.2, 





348.1073, found 348.1081. 
Methyl 3-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)propanoate 
(34) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.24 g, 1.57 mmol) was added to a 
solution of 32 (0.10 g, 0.47 mmol) in acetonitrile (15 mL). The resulting mixture was 
stirred for 0.5 h before adding methyl acrylate (0.14 g, 1.57 mmol). The reaction solution 
was heated to 50 °C and stirred for another 24 h. It was then diluted with ethyl acetate (50 
mL), and washed with brine (20 mL × 3). The organic layer was dried over Na2SO4, 
filtrated, and concentrated. The product was purified by column chromatography (silica 
gel, hexanes:acetone = 3:1 to 1:1) to afford 34 as an orange solid (0.084 g, yield 60%). 1H 
NMR (400 MHz, CDCl3) δ ppm 8.33 (d, J = 7.6 Hz, 1H), 7.79 (t, J = 8.4 Hz, 1H), 7.51 
(d, J = 8.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 4.60 (t, J = 6.8 Hz, 2H), 3.66 (s, 3H), 3.02 (t, 
J = 6.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ ppm 171.3, 151.8, 151.4, 151.2, 150.4, 
147.9, 135.5, 125.2, 123.3, 118.4, 110.8, 52.1, 37.9, 21.1. HRMS (ESI) calcd for 
C14H11N5O3 (M + Na)
+ 320.0760, found 320.0760. 
3-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)propanoic Acid (35). 
Compound 35 was synthesized using the same procedure as 33. Orange solid, yield 80%. 
1H NMR (400 MHz, DMSO-d6) δ ppm 12.46 (brs, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.85 (t, 
J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 4.48 (t, J = 6.8 Hz, 
2H), 2.83 (t, J = 7.2 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ ppm 172.7, 153.6, 
152.1, 152.0, 151.5, 148.7, 136.9, 125.0, 123.3, 118.5, 112.3, 32.1, 31.1. HRMS (ESI) 
calcd for C13H9 N5O3 (M + Na)
+ 306.0603, found 306.0612. 
4-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)butanoic Acid (37). 




65%. 1H NMR (400 MHz, DMSO-d6) δ ppm 12.08 (brs, 1H), 8.27 (d, J = 7.6 Hz, 1H), 
7.86 (t, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.41 (t, J = 7.2 Hz, 1H), 4.30 (t, J = 6.8 
Hz, 2H), 2.38 (t, J = 7.2 Hz, 2H), 2.07–2.00 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 
ppm 174.4, 153.7, 152.2, 152.0, 148.8, 136.1, 125.1, 123.3, 118.6, 111.8, 110.0, 41.1, 
31.2, 23.1. HRMS (ESI) calcd for C14H11N5O3 (M + Na)
+ 320.0760, found 320.0761. 
2-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)acetonitrile (38). 
NaH (60%) (0.007 g, 0.17 mmol) was added to a solution of 31 (0.03 g, 0.14 mmol) in 
DMF (10 mL) at 0 °C. The resulting mixture was stirred for 0.5 h at the same temperature 
before 2-bromoacetonitrile (0.02 g, 0.17 mmol) was added into it. It was then allowed to 
warm to rt gradually and stirred for another 1 h. The reaction mixture was then quenched 
with water (30 mL) and diluted with ethyl acetate (60 mL). The organic phase was 
washed with brine (20 mL × 2), dried over Na2SO4, and concentrated. The residue was 
purified by column chromatography (silica gel, hexanes:acetone = 5:1) to afford 38 
(0.025 g, 71% yield) as a yellow solid. 1H NMR (500 MHz, acetone-d6) δ ppm 8.37 (d, J 
= 8.0 Hz, 1H), 7.97 (t, J = 8.5 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 
5.51 (s 2H). 13C NMR (125 MHz, acetone-d6) δ ppm 152.7, 152.3, 151.7, 151.1, 147.17, 
136.0, 125.0, 124.2, 119.2, 114.3, 111.3, 29.4. HRMS (ESI) calcd for C12H6N6O (M + 
Na)+ 273.0501, found 273.0508. 
4-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)butanenitrile (40). 
Compound 40 was synthesized using the same procedure as 36.  Orange solid, yield 50%. 
1H NMR (400 MHz, DMSO-d6) δ ppm 7.61–7.64 (m, 2H), 7.16 (t, J = 7.6 Hz, 1H), 6.97 
(d, J = 8.0 Hz, 1H), 3.87 (t, J = 7.2 Hz, 2H), 2.48 (t, J = 7.2 Hz, 2H), 2.11–2.07 (m, 2H). 




109.8, 38.9, 23.6, 15.0. HRMS (ESI) calcd for C14H10N6O (M + Na)
+ 301.0814, found 
301.0808. 
3-(5H-[1,2,5]Oxadiazolo[3′,4′:5,6]pyrazino[2,3-b]indol-5-yl)propanenitrile (39). 
DBU (0.072 g, 0.47 mmol) was added to a solution of 31 (0.20 g, 0.95 mmol) in 
acetonitrile (10 mL). The solution was stirred for 0.5 h. Then, acrylonitrile (0.075 g, 1.4 
mmol) was added. The reaction solution was heated to 50 °C and stirred for 24 h. It was 
then diluted with ethyl acetate (50 mL), washed with brine (20 mL × 3). The organic 
layer was dried over Na2SO4, filtrated, and concentrated. The product was purified by 
column chromatography (silica gel, hexanes:acetone = 5:1 to 1:1) to afford 39 as orange 
solid (yield 62%). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.28 (d, J = 7.6 Hz, 1H), 7.89–
7.84 (m, 2H), 7.42 (t, J = 7.2 Hz, 1H), 4.61 (t, J = 6.8 Hz, 2H), 3.10 (t, J = 6.4 Hz, 2H). 
13C NMR (100 MHz, DMSO-d6) δ ppm 153.4, 152.0, 151.9, 151.5, 148.3, 136.2, 125.1, 
123.7, 119.1, 118.5, 112.2, 37.7, 16.4. HRMS (ESI) calcd for C13H8N6O (M + Na)
+ 
287.0657, found 287.0661. 
5-(2-(2H-Tetrazol-5-yl)ethyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-
b]indole (14). nBu3SnN3 (0.13 g, 0.38 mmol) was added to a solution of 39 (0.02 g, 0.076 
mmol) in toluene (10 mL). The resulting mixture was heated to reflux for 48 h. It was 
then cooled to rt, and the pH value was adjusted to 4–5 with HCl (1 M) and diluted with 
ethyl acetate (60 mL). The organic phase was washed with brine (20 mL × 2), dried over 
Na2SO4, and concentrated. The residue was purified by column chromatography (silica 
gel, CH2Cl2:MeOH = 10:1 to 5:1) to afford 14 (15.00 mg, 65% yield) as red solid. 
1H 
NMR (500 MHz, DMSO-d6) δ ppm 8.28 (d, J = 7.8 Hz, 1H), 7.81 (t, J = 8.1 Hz, 1H), 




Hz, 2H). 13C NMR (125 MHz, DMSO-d6) δ ppm 154.3, 153.8, 152.2, 152.2, 151.8, 
148.7, 136.3, 125.3, 123.7, 118.7, 111.9, 40.4, 22.3. HRMS (ESI) calcd for C13H9N9O (M 
– H)− 306.0852, found 306.0871. 
5-(3-(2H-Tetrazol-5-yl)propyl)-5H-[1,2,5]oxadiazolo[3′,4′:5,6]pyrazino[2,3-
b]indole (41). Compound 41 was synthesized using the same procedure as 14. Red solid, 
yield 57%. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.26 (d, J = 8.0 Hz, 1H), 7.85 (t, J = 
8.0 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 4.40 (t, J = 6.5 Hz, 2H), 
3.02 (t, J = 7.5 Hz, 2H), 2.32–2.26 (m, 2H). 13C NMR (125 MHz, DMSO-d6) δ ppm 
153.8, 152.4, 152.2, 151.9, 148.9, 136.4, 125.3, 123.6, 118.8, 112.1, 41.3, 25.6, 21.1. 
HRMS (ESI) calcd for C14H11N9O (M + Na)
+ 344.0984, found 344.0990. 
6H-indolo[2,3-b]quinoxaline (44). o-phenylenediamine (0.25 g, 2.3 mmol) was 
added to a solution of isatin (1.0 g, 6.8 mmol) in glacial acetic acid (10 ml) at rt. The 
mixture was heated to gentle reflux for 24 h and then poured into ice water. The resulting 
precipate was filtered to yield 44 as a yellow solid (0.36 g, 72% yield) 1H NMR (400 
MHz, DMSO-d6) δ ppm 12.02 (s, 1H), 8.34 (d, J = 7.6 Hz, 1H), 8.24 (d, J = 8.3 Hz,1H), 
8.06 (d, J = 8.3 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.70 (dd, J = 1.3, J = 7.2 Hz, 2H), 7.57 
(d, J = 7.9 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ ppm 
146.3, 144.4, 140.6, 140.2, 139.0, 131.8, 129.5, 129.2, 127.9, 126.4, 122.7, 121.1, 119.4, 
112.4. 
7,9-dichloro-6H-indolo[2,3-b]quinoxaline (45). Compound 45 was synthesized 
using the same procedure as 44. Yellow solid (yield 80%). Due to solubility issues, no 
NMR spectra for this compound were obtained.   




synthesized using the same procedure as 39. Yellow solid (56 % yield). 1H NMR (400 
MHz, DMSO-d6) δ ppm 8.50 (d, J = 7.7 Hz, 1H), 8.32 (dd, J = 1.1 Hz, J = 8.3 Hz, 1H), 
7.79 (ddd, J = 1.5 Hz, J = 6.9 Hz, J = 8.4 Hz, 2H), 7.76-7.70 (m, 2H), 7.56 (d, 1H, 
J=8.2Hz), 7.44 (t, 1H, J=7.6Hz), 4.81 (t, 2H, J=7.0Hz), 3.09 (t, 2H, J=7.0Hz). Due to 
solubility issues, no 13C NMR spectrum was obtained. 
3-(7,9-dichloro-6H-indolo[2,3-b]quinoxalin-6-yl)propanenitrile (47). Compoound 
47 was synthesized using the same procedure as 39. Yellow solid (55% yield). 1H NMR 
(400 MHz, DMSO-d6) δ ppm 8.41 (d, J = 2.0 Hz, 1H), 8.32 (dd, J = 1.1 Hz, J = 8.3 Hz, 
1H), (dd, J = 1.3 Hz, J = 8.4 Hz, 1H), 8.17 (dd, J = 1.2 Hz, J = 8.4 Hz, 1H), 7.84 (ddd, J 
= 1.5 Hz, J = 6.9 Hz, J = 8.4 Hz, 2H), 7.76 (ddd, J = 1.3 Hz, J = 7.0 Hz, J = 8.1Hz, 1H), 
7.67 (d, J = 2.0 Hz, 1H), 5.26 (t, J = 7.3 Hz, 2H), 3.08 (t, J = 7.3 Hz, 2H). Due to 
solubility issues, no 13C NMR spectrum was obtained. 
6-(2-(2H-tetrazol-5-yl)ethyl)-6H-indolo[2,3-b]quinoxaline (48). nBu3SnN3 (0.37 
g, 1.1 mmol) was added to a solution of 46 (0.060 g, 0.22 mmol) in toluene (20 mL) at rt. 
The resulting mixture was heated to reflux and stirred for 72 h. It was then cooled to rt 
and quenched with glacial acetic acid (10 ml). The resulting precipitate was filtered and 
washed with glacial acetic acid (10 ml) to afford 48 as a yellow solid. (0.10 g, 71% yield 
). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.34 (d, J = 7.7 Hz, 1H),  8.24 (dd, J = 1.3 Hz, 
J = 8.3 Hz, 1H), 8.04 (dd, J = 1.2 Hz, J = 8.4 Hz, 1H), 7.80 (ddd, J = 1.5 Hz, J = 6.9 Hz, 
J = 8.4 Hz, 1H), 7.74-7.68 (m, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 
4.84 (t, J = 6.8 Hz, 2H), 3.53 (t, J = 6.8 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ ppm 
145.4, 144.3, 140.2, 140.1, 139.2, 131.8, 129.5, 129.6, 127.9, 126.6, 122.7, 121.6, 119.1, 





Compound 49 was synthesized using the same procedure as 48. Yellow solid. Yield 69%.  
1H NMR (400 MHz, DMSO-d6) δ ppm 8.36 (d, J = 2, 1H), 8.314 (d, J = 8 Hz, 1H), 8.01 
(d, J = 8.4 Hz, 1H), 7.89 (d, J = 2 Hz, 1H), 7.85 (t, J = 8 Hz, 1H), 7.76 (t, J = 8 Hz, 1H), 
5.126 (t, J = 6.8 Hz, 2H), 3.521 (t, J = 6.8 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 
ppm 165.5, 146.1, 140.8, 139.7, 138.2, 138.2, 132.2, 130.5, 129.6, 128.1, 127.6, 126.2, 
123.7, 121.0, 117.2, 41.3, 24.5.  
 
2.3 Results 
2.3.1 High-throughput screening to discover drug-like, small-molecule β-
catenin/Tcf4 PPI inhibitors.  The high-throughput FP and AlphaScreen assays were 
previously optimized by Dr. Min Zhang for the discovery of β-catenin/Tcf4 PPI 
inhibitors.54 The FP assay used C-terminally fluorescein-labeled human Tcf4 peptide 
consisting of residues 7-51 and unlabeled human β-catenin ARM domain (residues 138-
686). Tcf4 was selected for labeling because the β-catenin/Tcf4 complex is over 10-fold 
larger than the fluorescein-labeled Tcf4. Therefore, it will exhibit the most depolarization 
when the large β-catenin/Tcf4 complex is disrupted. In the AlphaScreen assay, the 
streptavidin-coated donor bead is bound to a C-terminally biotinylated human Tcf4 
(residues 7-51), and the nickel-chelate acceptor bead is bound to a C-terminally 6X His-
tagged β-catenin ARM domain (residues 138-686). Laser excitation at 680 nm causes 
photosensitizers inside the donor bead to convert ambient oxygen into a higher energy 
singlet state. If the acceptor bead is within 2,000 Å  of the donor bead, as is the case in the 




Inhibition of the β-catenin/Tcf4 PPI will result in a larger distance between the donor and 
acceptor beads and a reduction in emission at 570 nM. Dr. Min Zhang screened 2,093 
compounds from multiple libraries: 24 compounds from the Zinc is Not Commercialized 
(ZINC) library, 90 compounds from the synthetic LOPACPfizer library, 117 natural 
products, 269 Sigma-Aldrich carboxylic acids and sulfonamides, and 1593 small 
molecules from the Diversity Set V from the Developmental Therapeutics Program of the 
National Cancer Institute/National Institute of Health. Compounds 12 and 20-22 inhibited 
the β-catenin/Tcf4 PPI in both FP and AlphaScreen assays (Figure 2.3). The most potent 
compound, 12, achieved apparent Ki values of 5.8 + 1.3 μM and 1.2 + 0.4 μM in FP and 
AlphaScreen assays, respectively.  Another potent dianion compound, 23, was discovered 
in the FP screening, but was not further evaluated. Dr. Min Zhang evaluated 12 and 20-22 
for cell-based inhibition of the Wnt signaling pathway through a TOPFlash luciferase 
reporter gene assay55 and MTS cell viability assay.56,57 Again, 12 was the most effective 
inhibitor tested. Compound 12 downregulated (IC50 = 0.71-0.86 μM) Wnt target gene 
transcription in a highly sensitive TOPFlash luciferase reporter gene assay (Figure 2.4A, 
and inhibited growth of colorectal cancer cells (IC50 = 0.85-1.1 μM) in a dose-dependent 
manner (Figure 2.4B).  Of these four inhibitors, only 12 proved effective in all assays, 
and was therefore selected for further study and optimization. 
2.3.2 Effects of 12 on Wnt target gene expression and protein expression levels.  
The effect of 12 on Axin2,58 cyclin D17 and c-myc6 Wnt target gene transcription was 
monitored by RT-qPCR by Dr. Min Zhang (Figure 2.5A). Compound 12 downregulated 
transcription in all tested Wnt target genes in SW480 cells. Transcription of the HPRT 





Figure 2.3. Top high-throughput screening compounds FP and AlphaScreen 
assay results. (A) FP assay results for top tested compounds. (B) AlphaScreen 
results of top compounds. Compound 23 was not tested in AlphaScreen because 
of the potential to interfere with the assay results. Adapted with permission from 
Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-
Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction 
through the Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 
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Figure 2.4. Cell-based assay results of top compounds. (A,B) Compound 12 exhibited the 
best inhibition of Wnt signaling in the TOPflash luciferase assay. (C) Compound 12 
exhibited the best inhibition of cancer cell growth in all three tested cell lines. (D) 
Compound 12 inhibits FOPFlash luciferase activity. Adapted with permission from 
Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule 
Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 4678-4692. 






Figure 2.5. Further testing of 12. (A) RT-qPCR results of 12. Compound 12 inhibited 
Wnt target gene transcription of all three tested genes (B) Western blot analysis of c-myc 
and cyclin D1 protein concentrations in the presence of 12. (C) Coimmunoprecipitation 
analysis of the ability of 12 to inhibit the β-catenin/Tcf PPI. Adapted with permission 
from Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule 
Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 4678-4692. 




Wnt target genes, cyclin D1 and c-myc, and β-catenin protein levels by 
coimmunoprecipitation and western blot analysis (Figure 2.5B). Compound 12 reduced 
Wnt target gene protein levels in a dose-dependent manner, but did not reduce protein 
levels of β-catenin or the β-tubulin control. These results indicated that 12 inhibited 
cellular Wnt signaling, but did not disrupt the highly important β-catenin degradation 
pathway. To test the ability of 12 to inhibit the cellular formation of the β-catenin/Tcf4 
complex, Dr. Min Zhang performed a second coimmunoprecipitation and western blot 
analysis. The results of this experiment indicated that 12 inhibited the formation of the β-
catenin/Tcf4 complex in SW480 cells (Figure 2.5C).  
 2.3.3 Removal of PAIN substructures and optimization of 12.  The structure of 12 
is not without problems. The first is the oxadiazolopyrazine structure which is similar to 
the benzafurazan PAIN substructure.30,59-61 The benzene ring of the benzafurazan moiety 
is potentially reactive with singlet oxygens62 and nucleophiles.63 However, it is unlikely 
that the oxadiazolopyrazine will suffer from these problems because of the lack of a 
benzene ring. The second PAIN substructure is the acyl hydrazone moiety.30 The acyl 
hydrazine moiety has been reported to be potentially reactive and cause frequent false 
positives in biochemical assays.64-66 The N-N single bond of the acyl hydrazone may be 
reactive with nucleophiles.64-66 However, 12 contains an intramolecular hydrogen bond 
between a nitrogen atom of the oxadiazolopyrazine and the hydrogen atom of the acyl 
hydrazone that may stabilize the structure.  Lastly, DNA intercalation is a concern with 
compounds containing large, planar heterocylic rings, but the hydrophobicity of the 





 Dr. Yongqiang Zhang performed a fragmentation study on compound 12 in order 
to better understand the manner in which 12 was able to inhibit the β-catenin/Tcf4 PPI. 
Compounds 24 and 25 were synthesized (Figure 2.6A), and 26-30 were purchased 
commercially. A condensation reaction between ninhydrin and 3,4-diaminofurazan 
resulted in fragment 23. Fragment 24 was generated by a condensation reaction between 
24 and hydrazine hydrate in glacial acetic acid. Compounds 24-30 were tested by the FP 
assay by Dr. Min Zhang (Figure 2.7). While most fragments exhibited some inhibitory 
activity, all were significantly less potent than 12.  
The optimization of 12 began with the resynthesis of 12 by Dr. Yongqiang Zhang 
(Figure 2.6B). To resynthesize 12, first 4-amino-1,2,5-oxadiazole-3-carboxylic acid was 
refluxed in methanol under acidic conditions to generate the methyl ester 42. 
Hydrazinolysis of 42 generated 43. A condensation reaction between 24 and 43 afforded 
compound 12 with moderate yield. The resynthesized 12 achieved Ki values of 7 + 4 μM 
and 1.7 + 3 μM in the FP and AlphaScreen assays, respectively. A blind docking of 12 
was conducted on the surface of β-catenin using AutoDock Vina47 to determine the 
possible binding sites.  AutoDock Vina scored the top poses for hot regions 1, 2, and 3, at 
-8.4, -4.6, and -3.7 kcal mol-1, respectively. Therefore, it was predicted that 12 
preferentially bound hot region 1. Compound 12 was docked into hot region 1 using 
AutoDock Vina, AutoDock4,51 and Schrödinger Glide53 to examine the binding mode. 
One binding mode recurred in all instances (Figure 2.8A). Most importantly, the 4-
amino-1,2,5-oxadiazole ring was predicted to act as a hydrogen bond acceptor for the 
side-chain of hot spot K435 and the backbone NH group of N430. The 






Figure 2.6. Synthetic schemes 1 and 2. Adapted with permission from Catrow, J. L.; 
Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule Inhibitors for the β-
Catenin/T-Cell Factor Protein–Protein Interaction through the Optimization of the Acyl 







Figure 2.7. FP assay results of fragmentation study. Adapted with permission from 
Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule 
Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 4678-4692. 






Figure 2.8. Docking and site-directed mutagenesis studies of inhibitors. (A) Results of 
Glide docking of inhibitors 12-14 and 37 representing the progression of inhibitor 
development (B) FP results of mutant β-catenins with compounds 12-14 and 37. Adapted 
with permission from Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. Discovery of Selective 
Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein–Protein Interaction 
through the Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 (11), 





K508. Other predicted interactions included a hydrogen bond between the amide 
carbonyl group of 12 and the side chains of N516 and S473. The large, heterocyclic ring 
structure was predicted to from a cation-π interaction with the side-chain of R469. The 
benzene ring was predicted to project into hydrophobic pocket B. Pocket B is not utilized 
by the β-catenin/Tcf4 interaction. Therefore, pocket B represents an excellent region to 
perform site-directed mutagenesis studies to evaluate the binding mode. Dr. Min Zhang 
created pocket B Β-catenin mutants R469A, V511S, and V511/I569S to test the binding 
mode of 12 (Figure 2.8B).16,39 FP binding assays using the mutant β-catenin and 
fluorescein-labeled Tcf4 indicated no change in the apparent Kd values of the mutant 
proteins. Resynthesized 12 achieved Ki values of 46 + 4, 20 + 2 μM, and 36 + 3 μM 
against R469A, V511S, and V511S/I569S mutant β-catenin/Tcf4 PPIs, respectively. 
These results indicate that 12 had some interaction with hot region 1. However, the acyl 
hydrazone PAIN substructure needed to be removed before further optimization could 
occur. Compound 13 was synthesized by Dr. Yongqiang Zhang to generate a small 
molecule similar to 12 but without the acyl hydrazone PAIN substructure. Isatin and 3,4-
diaminofurazan were refluxed in glacial acetic acid to yield 31 by a condensation  
reaction. Compound 32 was synthesized by reacting 31 with ethyl bromoacetate, and the 
ethyl ester was hydrolyzed to yield 36. Compound 13 was generated by peptide coupling 
of 3,4-diaminofurazan and 33. The potentially reactive imine carbon at the dibenzylic 
position of 12 was replaced with a nitrogen atom. This new compound, 13, is made more 
stable by completing an aromatic system within the heterocyclic ring yet is structurally 
similar to 12. The atoms responsible for hydrogen bonds with K435, K508 and the 




when tested by Dr. Min Zhang in the FP and AlphaScreen assays, 7 + 5 μM and 2.7 + 0.5 
μM, respectively. FP assay analysis of 13 with the previously described mutant β-catenin 
yielded similar results as 12 (Figure 2.8B), indicating that 13 bound to hot region 1.  
Once the acyl hydrazone PAIN substructure was removed, a series of inhibitors 
were designed to optimize the interaction between 4-amino-1,2,5-oxadiazole portion of 
13 and K435 (Figure 2.9). Because of the positively-charged amino group of K435, this 
series focused on creating compounds with carboxylic acids and tetrazoles, a carboxylic 
acid bioisostere, with a 1-4 carbon alkyl linker. An aza-Michael addition to 31 generated 
34 and 39, and nucleophilic substitution to 31 generated 34, 36, 38, and 40. Carboxylic 
acids 35 and 37 were generated by hydrolysis of 34 and 36, respectively. Tetrazoles 14 
and 41 were generated by a [2 + 3] cycloaddition reaction with 39 and 40, respectively. 
The ester compounds 32, 34, and 36 and nitrile compounds 38-40 showed poor ability to 
inhibit the β-catenin/Tcf4 PPI in the FP assay. 
Compounds 14, 33, 35, 37, and 41 inhibited the β-catenin/Tcf4 PPI in 
biochemical assays (Table 2.1). Of the new inhibitors, carboxylic acid 36 proved the most 
potent inhibitor in the FP and AlphaScreen assays, with Ki values of 3 + 1 μM and 1.0 + 
0.1 μM, respectively. Compound 14 was the most potent tetrazole compound tested with 
FP (17 + 2 μM) and AlphaScreen (18 + 2 μM).  
Compounds 14 and 37 were docked with AutoDock Vina, Schrödinger Glide, and 
AutoDock4 to evaluate the binding modes. The Glide docking results are shown in Figure 
2.10A. The docking modes of the new compounds are predicted to be similar to 12. The 
hydrogen bonds between the oxadiazolopyrazine ring and K508 were retained, as was the 






Figure 2.9. Synthetic scheme 3. Adapted with permission from Catrow, J. L.; Zhang, Y.; 
Zhang, M.; Ji, H. Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-
Cell Factor Protein–Protein Interaction through the Optimization of the Acyl Hydrazone 







Table 2.1 FP and AlphaScreen assay results of new compounds (Ki + S.D. [µM]). 
Compound FP result AlphaScreen result 
12 7.0 + 4 1.7 + 0.3 
13 7.2 + 5 2.7 + 5 
14 17 + 2 18 + 2 
31 2.8 X 102 + 10 1.2 X 102 + 9 
32 1.5 X 102 + 8 63 + 5 
33 5.8 + 2 4.1 + 0.5 
34 1.0 X 102 + 9 1.0 X 102 + 3 
35 11 + 4 3.30 + 0.6 
36 1.2 X 102 + 4 52 + 2 
37 3.4 + 1 1.0 + 0.1 
38 2.4 X 102 + 10 > 13 X 102  
39 47 + 5 39 + 2 
40 1.6 X 102 + 9 1.0 X 102 + 4 







Figure 2.10. FP assay results for β-catenin/Tcf4, β-catenin/E-cadherin 
and β-catenin/APC PPIs. All derivatives of 12 were selective for the β-
catenin/Tcf4 PPI. Adapted with permission from Catrow, J. L.; Zhang, 
Y.; Zhang, M.; Ji, H. Discovery of Selective Small-Molecule Inhibitors 
for the β-Catenin/T-Cell Factor Protein–Protein Interaction through the 
Optimization of the Acyl Hydrazone Moiety. J. Med. Chem. 2015, 58 





14 were predicted to interact strongly with hot spot K435. Hydrogen bonds with the 
backbone amide hydrogen of H470 and side chain hydroxyl of S473, and the 
hydrophobic interaction between the benzene and pocket B were also maintained. FP 
assays using the previously described mutant β-catenin were used to validate the binding 
modes of 14 and 37. Both 14 and 37 were responsive to the site-directed mutagenesis β-
catenin mutants in the FP assay (Figure 2.8B).  
Compounds 12, 13, 14, 33, 35, and 37 were evaluated for selectivity for the β-
catenin/Tcf4 PPI over the β-catenin/E-cadherin and β-catenin/APC PPIs. Selectivity was 
evaluated through the FP assay utilizing C-terminally fluorescein-labeled human Tcf4 
(residues 7-51), C-terminally fluoroscein-labeled human E-cadherin (residues 819-873), 
and C-terminally fluoroscein-labeled human APC (residues 1477-1519). With the 
exception of 12, all compounds tested showed good selectivity for the β-catenin/Tcf4 PPI 
(Figure 2.10). Compound 12 was not as selective as the other compounds, because the 
acyl hydrazone PAIN substructure caused nonspecific interactions with other hot regions. 
While these results are promising for the selective inhibition of the β-catenin/Tcf4 PPI, 
further study is required to better understand the selective nature of the inhibitors. 
2.3.4 Biological characterization of compound 12 derivatives.  Dr. Min Zhang 
evaluated 13, 14, 34, 36, and 37 with a TOPFlash Wnt reporter gene assay using 
pcDNA3.1-β-catenin transfected HEK293 cells. Only 14 downregulated the transcription 
of Wnt target genes in a dose-dependent manner (Figure 2.11A). The Wnt-independent 
FOPFlash luciferase activity remained unaffected even at high concentrations of 1(Figure 
2.10B). Similar results were observed when Dr. Min Zhang tested compounds 13, 14, 34, 







Figure 2.11. Cell-based assay testing of 14. (A) TOPFlash luciferase results for 14. (B) 
FOP-luciferase control. Compound 14 does not show off-target activity even at high 
doses. (C) RT-qPCR results for 14. Compound 14 inhibits Wnt target gene transcription, 
while the HRPT transcription remains unaffected. (D) MTS cell viability assay for 14 and 
39. Compound 14 inhibited the growth of both SW480 and HT115 colorectal cancer 
cells. Adapted with permission from Catrow, J. L.; Zhang, Y.; Zhang, M.; Ji, H. 
Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor 
Protein–Protein Interaction through the Optimization of the Acyl Hydrazone Moiety. J. 




assay. Again, only 14 inhibited growth of SW480 and HCT116 cell lines with an IC50 of 
20 + 4 μM and 31 + 6 μM, respectively (Figure 2.11D). Compound 39 inhibited the 
growth of SW480 cells but not HCT116 cells (Figure 2.11D). Additionally, 14 
downregulated Axin2 gene transcription when examined by RT-qPCR (Figure 2.11C). 
The inactivity of the other compounds may be due to low cell permeability in the tested 
cell lines. 
To evaluate the ability of these compounds to inhibit the Wnt signaling pathway 
in vivo, Dr. David Hutcheson and Janelle Tardif tested 36 in a transgenic Wnt reporter 
zebrafish model (Figure 2.12).71,72 The headless mutation in zebrafish has been linked to 
the canonical Wnt signaling pathway.73 Dorsky et al.72 developed a transgenic zebrafish 
line (TOPdGFP) which expresses destabilized green fluorescent protein (dGFP) when 
canonical Wnt signaling is active. Therefore, a positive result for the disruption of Wnt 
signaling is reduced expression of dGFP in the head and eye region. Zebrafish embryos 
were exposed to 2 µM and 10 µM of 36. The zebrafish embryos exposed to 10 µM of 36 
showed markedly less development in the eye and brain. Transgenic embryos exposed to 
2 µM and 10 µM of 36 showed a dose-dependent response. While these results are quite 
preliminary, they highlight the ability of 36 to disrupt the Wnt signaling pathway in vivo. 
2.3.5 Further development of biologically active Β-catenin/Tcf4 PPI inhibitors.  
One of the largest problems facing 31 is the low synthetic yield, 15-18%. This was 
hypothesized to be due to the electron-poor nature of 3,4-diaminofurazan. To remedy 
this, the starting material 3,4-diaminofurzan was replaced with ortho-phenylenediamine 
(Figure 2.13).74 The resulting reaction had a dramatically increased yield of 80%. 






Figure 2.12. Results of compound 36 on transgenic zebrafish model. (A) Developmental 
effects on the head and eye region as a result of treatment with 10 µM 36. (B) Expression 
of dGFP in TOPdGFP zebrafish embryos exposed to varying concentrations of 36. 











cells, compounds 48 and 49 were created. Compounds 48 and 49 were synthesized using 
the same synthetic route as 14. 
A ligand-based structure activity relationship study was planned for this series of 
inhibitors to explore adding additional hydrophobic interactions to pocket B. 
Undergraduate ACCESS fellow Brooklyn Brakey synthesized 49 for this study. 
Compounds 48 and 49 were tested by Dr. Min Zhang in the FP assay and obtained Ki 
values of 66 + 7 µM and 12 + 1 µM, respectively (Figure 2.14A).  Compound 48 had 
reduced activity compared to 14. This reduction is likely due to the loss of a hydrogen 
bond from the furazan nitrogen with K508. The addition of the chlorine at the 5-position 
of the isatin ring is predicted by AutoDock Vina to interact with pocket B, resulting in 
increased activity (Figure 2.14B).  These final two compounds were submitted to Dr. 
Katrin Guillen of the Welm lab for testing on mammary epithelial cells (MECs)75 (Figure 
2.15). MECS were embedded in matrigel (4 µL base, 8 µL dome, 200 agg/dom) and 
treated with compounds 14, 37, 48, and 49 48 h post embedding and again at 96 h post- 
embedding. The effects of these compounds on the cells were scored 144 h post- 
embedding. Compound 48 produced the best result with all of the cells in either a cyst or 
solid state. Compound 49 induced the solid extruding cell type, indicating mild 
cytotoxicity. Compounds 14 and 37 had less activity. Despite the promising results in the 
TOPdGFP zebrafish and primary cell MEC 3D screen, there is still much to do in order to 






Figure 2.14. Results of 48 and 49. (A) Compounds 48 and 49 show an inhibitory effect 






Figure 2.15. Results of testing compounds on MECs. Compound 45 proved most capable 




2.4 Discussion  
 Because the aberrant activation of the Wnt signaling pathway is responsible for 
many diseases, there is an urgent need to develop selective, small-molecule Wnt 
inhibitors.9 The β-catenin/Tcf4 PPI is the penultimate step of the Wnt signaling pathway 
and represents an appealing target for small-molecule Wnt inhibitors. Because E-cadherin 
and APC overlap the Tcf4 binding site on β-catenin, a small molecule inhibitor of the β-
catenin/Tcf4 PPI must be selective for inhibition of the β-catenin/Tcf4 over the β-
catenin/E-cadherin and β-catenin/APC PPIs. This selectivity is important because a small 
molecule that disrupts the β-catenin/E-cadherin or β-catenin/APC PPIs risks disrupting 
cell adhesion networks or the β-catenin degradation pathway.  
Finding effective, selective, PAIN substructure-free inhibitors of this PPI has 
proven difficult. In this study, FP and AlphaScreen identified 12 as an inhibitor of the β-
catenin/Tcf PPI. Compound 12 was effective at inhibiting Wnt target gene activation and 
cancer cell growth. However, 12 contained the acyl hydrazone PAIN substructure. The 
acyl hydrazone moiety has been implicated as causing false positives and is possibly 
reactive with nucleophiles.30 The formation of this substructure is an important 
component of DCC because it is reversible and controllable by pH change.42 The acyl 
hydrazone moiety can also act as both a hydrogen bond donor and acceptor, thereby 
increasing the potency of the discovered molecule.42 Though many biologically active 
acyl hydrazone-containing molecules have been reported, this substructure is only found 
in two clinically accepted small-molecule drugs. Therefore, a careful evaluation of any 
acyl hydrazone containing molecule must be made before proceeding with optimization. 




while maintaining inhibitor potency. By replacing the acyl hydrazone with a peptide 
bond, the potentially unstable N-N single bond was removed.  Docking studies of 12 and 
13 ensured that a similar predicted binding mode was maintained even after the acyl 
hydrazone was removed. These compounds interacted with hot region 1, which has been 
previously established as a site to selectively inhibit the β-catenin/Tcf4 PPI.  
The further optimization of 13 was performed to generate compounds 14 and 37. 
Compounds 14 and 37 were predicted to form charge-charge interactions with the β-
catenin hot spot K435 and increase inhibitor potency and cell-based activity. This hot 
spot, which interacts with D16 of human Tcf4, was shown to be crucial for the β-
catenin/Tcf4 PPI. Compounds 13, 14, and 37 achieved increased selectivity for the β-
catenin/Tcf4 PPI compared to 12. This increased selectivity is likely a result of less 
promiscuous binding due to the removal of the acyl hydrazone PAIN substructure. 
Compound 14 also downregulated Wnt target gene transcription in a TOPFlash luciferase 
reporter gene assay and inhibited the growth of Wnt-active colorectal cancer cells. 
Compound 44 was created to overcome the low yield of the first step in the 
synthesis of 31. Compound 49 was synthesized from 44 to increase interaction with 
hydrophobic pocket B of hot region 1.  Compound 49 showed increased inhibition of the 
β-catenin/Tcf4 PPI compared to 14 in biochemical testing. Additionally, 48 and 49 were 
effective at inhibiting the growth of MECs. 
 
2.5 Conclusion 
 Small-molecule inhibition of PPIs is a challenging field of medicinal chemistry. 




contacting surfaces involved.11 Selective inhibition of the β-catenin/Tcf4 PPI is 
complicated by binding site overlap between Tcf4, E-cadherin and APC. These three 
proteins share three hot regions on β-catenin.22 However, hot region 1, containing key 
lysine residues K435 and K508, is the most important hot region for Tcf4 binding. 
Previous studies with UUT-02 have shown that inhibitors binding this hot region are 
capable of selective inhibition of the β-catenin/Tcf4 PPI.39  
Biochemical and cell-based assays identified 12 as a selective, drug-like, small-
molecule inhibitor of the β-catenin/Tcf4 PPI. Site-directed mutagenesis assays confirmed 
that 12 bound to hot region 1 of β-catenin. The acyl hydrazone PAIN substructure was 
identified in 12. Compound 12 was optimized to generate 13, 14, 37, 48, and 49 which 
lack the acyl hydrazone substructure. Compounds 13, 14, and 37 achieved greater 
selectivity for the β-catenin/Tcf4 PPI than 12. Site-directed mutagenesis confirmed that 
these inhibitors utilized a similar binding mode in hot region 1 as 12. This further 
confirms the use of hot region 1 of β-catenin as a small molecule binding site to 
selectively inhibit the β-catenin/Tcf4 PPI. This series of inhibitors has also exhibited the 
ability to inhibit Wnt signaling in vivo, as 35 was shown to inhibit Wnt signaling in 
zebrafish, and 48 inhibited growth of MEC cells.  
Even though the selectivity is still lower than what could be desired, it should be 
noted that in the biochemical assays, Tcf4 is the tightest binding partner.15,23,24 Therefore, 
the selectivity of these molecules is significant. Further optimization could increase 
binding to hot region 1 and increase selectivity. Compound 49 was used to explore this 
by utilizing Cl atoms to occupy pocket B. In addition to further optimizing the pocket B 
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HIGH-THROUGHPUT VIRTUAL SCREENING CHALLENGES 




PPIs play a crucial role in regulating biological pathways. The dysregulation of 
these pathways results in diseases. PPIs are ubiquitous, and more than 40,000 PPIs have 
been experimentally identified with even more predicted.1–3 The abundance of PPIs and 
their high relevance in disease makes them desirable drug targets, and targeting these 
interactions will greatly expand the druggable genome. Despite their therapeutic appeal, 
the discovery of small molecules to disrupt these interactions has been met with 
difficulty. Notably, few PPI inhibitors have advanced to clinical trials.4 
Nontraditional PPIs differ from traditional drug targets such as GPCRs, kinases, 
proteases, and other enzymes. These differences are predominantly related to the size, 
shape, and chemical characteristics of PPI interfaces.5 PPIs have large contacting surface 
areas, upwards of 3,000 Å2, in contrast to traditional drug targets that have contacting 
surface areas of less than 1,000 Å2. Traditional targets often display an active site with 
deep, well-defined pockets containing residues that readily bind a substrate or catalyze a 
reaction. PPI binding sites are often flat, shallow, and devoid of catalytic residues. When 
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taken as a whole, these compounding factors result in several challenges for the discovery 
of small-molecule inhibitors.6,7 Regardless of the problems associated with the PPI 
interface, this group of nontraditional drug targets comprise a large portion of the 
druggable genome but constitute a disproportionately small number of therapeutic 
targets.  
One strategy for overcoming the challenges presented by PPI interfaces is the use 
of hot spots.8–10 These are the regions at the PPI interface containing residues that exhibit 
a ΔΔG of > 1.5 kcal mol-1 when examined by alanine scanning.8 Hot spot residues on the 
target protein are often preorganized into pockets that reside on the PPI interface.11,12 The 
surrounding residues help occlude solvent from the hot spot pockets, thereby reducing 
entropic and enthalpic penalties for binding.12 Hot spots function similarly to “anchor 
residues” proposed by Rajamani et al.13 By use of anchor residues, large solvent 
accessible surface areas (SASAs) of one protein binding partner are buried through 
interactions with the anchor residues of the other protein partner. Hot spots present a site 
where small molecules may more efficiently bind and disrupt PPIs.14 Hot spots have been 
successfully used for structure-based design, high-throughput screening and HTVS of 
PPI inhibitors.15-20 Although high-throughput screening, rational design, and 
peptidomimetic strategies have achieved varying levels of success, HTVS provides an 
inexpensive starting strategy for obtaining hits from large virtual libraries of millions of 
compounds. 
Despite the advantages, HTVS has had limited success for discovering PPI 
inhibitors. Table 3.1 surveys PPI inhibitors identified through HTVS as well as the 
docking programs and the supplementary techniques used to discover them. Docking 
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algorithms and scoring functions for most docking software, including Glide and 
AutoDock were validated using a test set of traditional drug targets.20–23 This has 
necessitated the use of alternative methods to enhance HTVS results for PPI targets.20 As 
shown in Table 3.1, the use of supplementary techniques that go beyond scoring and 
ranking potential hits has been common and highlighted the need to improve HTVS for 
PPIs. The supplementary techniques include molecular mechanics based calculation of 
theoretical binding energies,24,25 the use of hot spot knowledge,15–19 and pharmacophore 
modeling.26-32 Pharmacophore modeling approaches have been used to discover small-
molecule PPI inhibitors for murine double minute 2 homolog (MDM2)/p53, Abelson 
murine leukemia viral oncogene homolog 1 kinase (c-Abl)/14-3-3, Lens epithelium-
derived growth factor (IN-LEDGF)/p75, interferon (IFN)/Interferon alpha/beta receptor 1 
(IFNAR), and S100B/p53 PPIs.26–32 The other methods have been developed to aid 
HTVS for discovering PPI inhibitors. Geppert et al. combined the methodologies for 
molecular descriptors, pharmacophore modeling, and HTVS to search inhibitors for 
IFN/IFNAR and trypsin-inhibitor/trypsin PPIs.30,31 Molecular mechanics/Poisson-
Boltzmann Surface Area (MM/PBSA) physics-based calculations were performed to aid 
in re-ranking HTVS results for the Toll-like receptor 4 (TLR4)/Lymphocyte antigen 96 
(Md2) PPI.26 Hot spot pocket knowledge has been used to enhance HTVS results for 
cytohesin-2 (Arno)/ adenosine diphosphate Ribosylation Factor 1 (Arf1) and negative 
regulatory factor (NEF)/SH3-domain PPIs15,33 as well as the discovery of submicromolar 
inhibitors for Gβγ subunit-mediated PPIs.16 The protruding hot spots of the ligand protein 
at the PPI interface have also been used as the template for HTVS to discover Ras-related 
C3 botulinum toxin substrate 1 (Rac1)/ T-lymphoma invasion and metastasis-inducing 
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protein 1 (Tiam1) inhibitors.34 Despite the use of these complementary techniques, most 
small molecules discovered through HTVS for PPIs achieve only micromolar activities 
with low success rates. 
On the other hand, it is possible to discover or design potent inhibitors for PPIs. 
Techniques such as structure–activity relationship (SAR) by NMR,35,36 high-throughput 
screening by fluorescence polarization37 or luminescent reporter assays,38 and structure-
based design39 all have produced small-molecule inhibitors with submicromolar potency. 
Inhibitors with nanomolar to subnanomolar potency have been developed for X-linked 
inhibitor of apoptosis protein (XIAP)/baculovirus inhibitor of apoptosis protein repeat 3 
(BIR3),40 menin/mixed lineage leukemia protein (MLL),41 MDM2/p53,42 bromodomain-
containing protein 4 (BRD4)/histone,43,44 calpain/calpastatin,45 Bcl-2/BH3-domain,46 Bcl-
XL/BH3-domain,
36,47 and WD repeat protein 5 (WDR5) /MLL PPIs.48,49 These examples 
prompted us to investigate the factors that might be able to increase the HTVS hit rate of 
small-molecule PPI inhibitors. 
One approach to enhancing the rate for the discovery of more potent PPI 
inhibitors through HTVS is to identify the compounds that are more likely to bind hot 
spots.15,16 A higher degree of ligand burial will be more likely to have higher ligand 
efficiency due to more contacts with the binding site. Mysinger et al. pointed out the 
problems of current scoring functions and the need to select small molecules that engage 
all of their functional groups with the target protein in their HTVS to discover small-
molecule inhibitors for the chemokine receptor (CXCR4)/chemokine (CXCL12) PPI.50 
More importantly, the ligand will be more likely to interact with the hot spot pocket 
because it may induce the pocket formation.6,7 In a recent paper comparing traditional 
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drug targets with PPIs, Gowthaman et al. described a property of inhibitors relating to 
their binding of shallow PPI surfaces.24,25 This property, called θl, is the fraction of the 
bound over unbound SASAs of the inhibitor, as shown in Figure 3.1.24,25 Evaluation of 
the SASA has proven to be useful tool to better understand PPIs. Indeed, the amount of 
buried surface area between two protein-protein interacting partners correlates with the 
Kd.
51 The more buried the two PPI partners are in each other, the lower the Kd. Examining 
the SASA has also provided the ability to computationally detect PPI hot spots.13 
Furthermore, SASA has proven a useful tool in determining the location where a small 
molecule likely binds.52,53 Therefore, the basis for using SASA in evaluation of inhibitor 
burial is well supported. While θl is likely relevant for the inhibitors of both traditional 
and nontraditional targets, it is particularly important for PPI inhibitors because hot spot 
residues are often more buried in the PPI interface.5,6 As the buried surface area was 
correlated with the PPI Kd, it was hypothesized that θl may be the equivalent measure of 
this relationship between small-molecule inhibitors and PPI targets. 
Gowthaman, et al. concluded that traditional virtual screening software was ill 
adapted for PPIs.24,25 They found that PPI inhibitors were more solvent exposed and have 
lower ligand efficiency than their traditional target counterparts. The authors stated that θl 
did not correlate with inhibitor potency between traditional and PPI targets or between 
different PPI targets. Herein, the relationship between θl and inhibitor potency for a 
single PPI target and the relationship between θl and the other HTVS associated 
properties are explored. The goals were to evaluate the feasibility of using θl to aid in 
identifying potent PPI hits and identify the determinants that affect the use of HTVS tools 
for the discovery of small-molecule PPI inhibitors. 
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Figure 3.1. Illustrated example showing the differences in ligand burial. The inhibitor for 
the PPI site has a higher θl value because more of the ligand is solvent exposed compared 
to the lower θl of the enzyme inhibitor. 
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3.2 Methods 
3.2.1 MDM2 crystal structure inhibitor study.  Crystal structures of human or 
humanized MDM2 in complexes with potent small-molecule inhibitors for the 
MDM2/p53 PPI (3VZV,55 3W69,56 4OBA,41 4ERE,41 4ERF,41 4OQ3,57 4ODE,58 
4OGN,60 4OGT,60 4OGV,60 4OCC,60 4ZYF,59 4ZYI,61 4LWU,60 4JVE,61 4JVR,63 
4QO4,62 4IPF,63 4QOC64, 4OAS45) were retrieved from the RCSB server. The structures 
and biological activities of these potent MDM2-bound inhibitors (IC50 ≤ 100 nM) are 
shown in Figure 3.2. Ligands were prepared by adding appropriate bonds and hydrogen 
atoms using Schrödinger Maestro.65 Proteins were prepared using the Schrödinger protein 
preparation workflow.66,67 SASA calculations were carried out using the Schrödinger 
script atomic_sasa.py. The SASA was measured for the bound and unbound ligand 
structures. The fraction of SASA exposed for an inhibitor-protein complex, θl, was 
calculated by dividing the SASA of the bound ligand to that of the unbound ligand. The 
same 3D structure was used for the SASA calculations of the unbound ligand. Statistical 
analyses were performed using Microsoft Excel and Schrödinger Strike (Figure 3.3a).68 
3.2.2 Bcl-XL study.  Compounds 1a, 1b, 8a-e, 8h, 8i, 8k, 8n, 10f, 10g, 10i, 10j, 
14a, 14b, 18, 21, 22, 23a, 23b, 23e, 23f, and 23p from Bruncko and colleagues’ study of 
the structure-guided design and synthesis of Bcl-XL and Bcl-2 dual inhibitors
69 were 
prepared using Schrödinger Ligprep and were protonated for physiological pH70. The 
structures and biological activities of these Bcl-XL inhibitors are shown in Figure 3.4. 
These inhibitors represent the SAR study in which their Ki values were definitive, above 
the limit of detection, and more selective for Bcl-XL over Bcl-2. The NMR structures of 
Bcl-XL (PDB IDs 2O1Y, 2O2M, and 2O2N) were prepared using the Schrödinger  




Figure 3.2. Structures and biological activities of MDM2/p53 PPI inhibitors. 
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Figure 3.2. Continued.  
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Figure 3.3. Workflows to evaluate the key factors for HTVS to discover inhibitors for 
PPIs. (A) Evaluation of the relationship between the burial and the potency of 
MDM2/p53 inhibitors that are co-crystalized with MDM2. (B) Evaluation of the 
relationship between the burial and the potency of a series of Bcl-XL inhibitors. (C) The 
docking studies of approximately 10,000 test compounds using AutoDock Vina and 
Schrodinger Glide for five PPI targets. The flowchart shows the algorithms for pose 
prediction and the steps for evaluation of the scoring functions.  
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Figure 3.4. Structures and biological activities of Bcl-XL/BH3-domain PPI inhibitors. 
Asterisk indicated mean ± standard error for three or more experiments run in duplicate 
for 8a.69 
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protein preparation workflow69. Ligands were docked using AutoDock Vina with a 30 Å 
grid centered on the structure of the bound ligand encompassing all relevant residues. The 
exhaustiveness parameter was set to 12. Nine docked poses were generated for each 
compound. SASA calculations were carried out using the Schrödinger atomic_sasa.py 
script. The inhibitor poses were visually analyzed for features such as the sizes and 
shapes of the inhibitors. Statistical calculations were carried out using the data of the 
complex chosen as the best fit for each ligand based on visual shape similarity (Figure 
3.3B). Statistical tests were calculated using Microsoft Excel and Schrödinger Strike.70 
3.2.3 Docking study.  Structures representing five potent PPI inhibitors in 
complexes with their respective targets were chosen to evaluate the performance of 
HTVS. These five structures are the XIAP-BIR3 domain (PDB ID, 1TFT)71, Bcl-XL 
(PDB ID, 1YSI)36, BRD4 (PDB ID, 2YEL)40, WDR5 (PDB ID, 3UR4)72, and MDM2 
(PDB ID, 4ERF)41 and were downloaded from the RCSB web server. The receptor was 
prepared by removing all crystallographic waters, solvents, and ligands. Receptor 
structures were processed using the Schrödinger protein preparation workflow.69 Missing 
side-chain atoms were added using Schrödinger Prime.73,74 A subset of 10,000 structures 
from the ZINC library for HTVS with properties similar to that of the inhibitors used in 
Gowthaman and colleagues' study24,25 was downloaded and prepared through 
Schrödinger Ligprep. These inhibitors have molecular weights between 200 and 750 Da, 
net charge between –1 and +2, and xlogP between –4.9 and +6.5. The protonation state 
was generated at pH = 7.0 using Epik69. Ligand structures encountering an error on any 
part of the preparation were discarded resulting in 9,300 structures. The native ligands 
from the crystal structures were extracted and prepared identically with that of the test 
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set. A cubic grid was generated for each structure centered on the bound ligand with a 
size of 30 Å3. Ligands were docked using the Glide standard precision (SP)27,58 default 
settings and the enhanced planarity for conjugated π systems. Ser, Thr, and Tyr side chain 
hydroxyl groups were allowed to rotate. A single output pose was generated for each 
docking job. Ligands were docked using Autodock Vina76 with grid parameters similar to 
the Glide grid with exhaustiveness of 12. Nine poses were generated for each docked 
small molecule. The output poses from AutoDock Vina were rescored in place using 
Glide SP. Further, the output poses of both AutoDock Vina and Glide SP docking were 
rescored using Schrödinger Prime MM/GBSA calculations77 with a minimization 
method. MM/GBSA enrichment was defined as the scoring rank divided by the 
MM/GBSA rank. SASA calculations were carried out using the Schrödinger 
atomic_sasa.py script. Statistical calculations were performed using Microsoft Excel.70 
To examine the correlation between docking scores and θl values, the known inhibitors 
were docked to its respective PPI target with AutoDock Vina. The settings were 
nummodes = 20, exhaustiveness =  12, energy_range = 5. Twenty poses were generated 
for 1TFT, 1YSI, 3UR4, and 4ERF. The docking of the ligand for 2YEL generated 19 
poses. SASA and θl calculations and statistical analyses were performed using Microsoft 
Excel and Schrödinger Strike.70 
 
3.3 Results  
3.3.1 MDM2 crystal structure inhibitor study.  A correlation was observed 
between IC50 and θl for the examined MDM2/p53 PPI inhibitors with Spearman’s rho 
(|rs|) = 0.327 (Figure 3.5a). The observed correlation was statistically significant at 90%  




Figure 3.5. Correlation between inhibitor burial and ligand potency. (A) A moderate 
correlation was observed between inhibitor potency (pIC50) and burial (θl) for 20 
MDM2/p53 inhibitors. (B) Correlation between θl and Ki for a series of inhibitors for the 
Bcl-XL/BH3-domain PPI. Compound 8a was marked with a triangle due to the larger 
error in the measurement of its Ki value. 
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confidence (α = 0.1) for the size of the data set (n = 20). The inhibitors from structures 
4ODE, 4OGN and 4OGT appear to be more potent than the other inhibitors that are 
equally buried. These inhibitors gain much of their extra potency from the strong ionic 
interaction with hot spot residue H96.60 The other outlier of the group, 4JVE, is relatively 
not as potent despite its high degree of burial. The analysis of the binding mode of the 
inhibitors in the crystal structures showed that most of the potency was derived from 
hydrophobic contacts and most structures lack the ionic and hydrogen bonding 
interactions that were observed in 4ODE, 4OGN, and 4OGT. When these structures were 
removed, a stronger relationship was observed between IC50 and θl with |rs| = 0.503 (n = 
16). This correlation was statistically significant at the 90% confidence interval. These 
data led to the conclusion that ligand burial was important, but secondary to the strong 
non-bonding interactions with the hot spot residues. 
3.3.2 Bcl-XL inhibitor study.  A correlation, shown in Figure 3.5B, was observed 
between θl and Ki in a series of Bcl-XL inhibitors (|rs| = 0.370, α = 0.05, n = 25). 
Compound 8a was observed to have a higher Ki than the rest of the data set. Compound 
8a likely represents a case where the effect of θl is eclipsed by the other factors. If the 
data point for 8a is removed because it has a relatively large reported standard error 
value71 (standard error = 1.2) and the relatively higher Ki value, the |rs| value rises to 
0.450 and shows a stronger correlation (n = 24). 
3.3.3 Docking study.  Table 3.2 and Figure 3.6 show a summary of the docking 
and scoring results. The success of the docking study was defined by two criteria: (1) the 
top-scored docking pose of the bioactive compound was similar to the crystallographic 
binding conformation; (2) the potent inhibitor observed in the crystal or NMR structure 
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(rmsd = 1.68 Å) 
successful 
(rmsd = 1.22 Å) 
failure 1.8  102 0.16 
1YSI 
scoring failure 
(rmsd = 1.53 Å) 
pose failure 
(rmsd = 11.3 Å) 
failure 0.83 0.81 
2YEL 
pose failure 
(rmsd = 2.43 Å) 
pose failure 
(rmsd = 3.99 Å) 
failure 0.011 0.2 
3UR4 
pose failure 
(rmsd = 2.05 Å) 
scoring failure 
(rmsd  = 1.63 Å) 
successful 0.55 0.22 
4ERF 
scoring failure 
(rmsd  = 1.33 Å) 
successful 
(rmsd  = 0.579 Å) 
successful 7.2  102 96 
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Figure 3.6. Comparison of the docked poses generated by Schrodinger Glide and 
AutoDock Vina. The crystallographic or NMR poses are shown green. The poses that 
were predicted by AutoDock Vina and Schrodinger Glide SP were colored magenta and 
blue, respectively. AutoDock Vina was more successful in pose prediction, but Glide 
proved to be more accurate for three instances — 1TFT, 3UR4, and 4ERF. 
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as scored within the top 1,000 out of all the compounds in the test set. Based on the two 
criteria, AutoDock Vina successfully identified a single complex, 1TFT. The inhibitors of  
structures 1TFT, 1YSI, 2YEL, 3UR4, and 4ERF achieved the docking poses with root-
mean-square deviations (rmsds) of 1.68 Å, 1.53 Å, 2.43 Å, 2.05 Å, and 1.33 Å, 
respectively. The docking results for 2YEL and 3UR4 were pose failures because their 
rmsds from the crystallographic binding conformations were > 2 Å, as shown in Table 
3.1. The 2YEL pose failure was the result of an incorrect amide bond dihedral angle. The 
rmsd of the docking pose for 3UR4 was just out of the boundary of our definition of a 
good pose (rmsd = 2 Å). This pose is still acceptable and can be useful for guiding 
inhibitor optimization. It should be noted that the fourth pose ranked by the AutoDock 
Vina scoring function for 3UR4 had an rmsd of 1.19 Å, but this pose was not counted as 
a success because only the first pose would be considered in virtual screening. Glide SP 
had two successes, 1TFT and 4ERF, with rmsds of 1.22 Å and 0.579 Å, respectively. 
3UR4 was a scoring failure, but achieved an rmsd of 1.68 Å. The Glide results for 1YSI 
and 2YEL were pose failures with rmsds of 11.3 Å and 3.92 Å, respectively. The re-
scoring of the AutoDock Vina poses using Glide score-in-place resulted in two successes 
for the top picks (3UR4 and 4ERF). The sole original success in the AutoDock Vina 
study, 1TFT, was scored worse by Glide score-in-pace. The result for 2YEL was not 
improved by Glide score-in-place likely due to the initial AutoDock Vina pose failure. 
An enrichment value was calculated when the poses were re-evaluated using MM/GBSA. 
Enrichment was defined as rank of docking score divided by the rank of MM/GBSA 
energy. A positive enrichment (enrichment > 1) meant that the ranking was improved by 
the MM/GBSA energy calculation, while a negative enrichment (enrichment < 1) refers 
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to when the inhibitor was scored worse by MM/GBSA than the scoring function. As 
shown in Table 3.2, two inhibitors from the AutoDock Vina study, 1TFT and 4ERF, were 
significantly positively enriched. One inhibitor from the Glide study, 4ERF, was also 
positively enriched. All remaining structures from both studies were not enriched in the 
MM/GBSA ranking. 
The θl results did not correlate with the docking scores or the MM/GBSA 
ΔΔGbinding values between different ligands. The θl values provided no enrichment in 
ranking the known potent inhibitors that were complexed in the crystal or NMR 
structures. However, when examining the relationship between the AutoDock Vina score 
and θl, we found a moderate-to-strong correlation (|rs| = 0.318-0.769) between these two 
variables within the same ligand, as shown in Figure 3.7. The correlation was significant 
(α = 0.1) for the docking poses in all of the PPI targets. 
 
3.4 Discussion 
The MDM2/p53 PPI is a high priority target due to its involvement in many 
aggressive and therapy-resistant cancers.77 As a result, many classes of inhibitors have 
been developed for this PPI.78 This has made the MDM2/p53 PPI the preferred target 
from which to begin the study of ligand burial in PPI inhibitors. Gowthaman et al.20 did 
not observe a statistically significant relationship between θl and inhibitor potency when 
comparing traditional targets with PPIs or between different PPI complexes. This is likely 
because the property θl is relative to both inhibitor and protein structures, so such a 
comparison between different protein structures might be inaccurate.24,25 In the 
Gowthama. study, the value of θl indeed varies significantly across different 




Figure 3.7. Correlation between docking score and ligand burial. Varying levels of 
correlations between θl and the AutoDock Vina score were observed for the PPI targets. 
This indicates that AutoDock Vina tends to score more buried poses higher than less 
buried poses. This is likely because the more buried the ligand is, the more favorable 
interactions it may have with the receptor.  
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inhibitor–protein complexes. The work presented in this study was focused on a single 
target, the MDM2/p53 PPI. The studied crystal structures were complexed with potent, 
nonfragment, small-molecule inhibitors (IC50 < 100 nM). In this data set a moderate but 
significant correlation between inhibitor potency (IC50) and the fraction of the ligand that 
remains solvent exposed (θl) was found. This relationship was not more strongly 
correlated because ligand burial was secondary to strong nonbonding interactions. The 
examination of the inhibitor binding mode in MDM2 crystal structures, 4ODE, 4OGT, 
and 4OGN, indicated that the inhibitors gained more potency through ionic interactions 
with an additional MDM2 hot spot, H96. On the other end of the spectrum was 4JVE, in 
which the inhibitor was as buried as 4ERE and 4ERF but exhibited much weaker potency 
due to the absence of strong ionic and/or hydrogen bonds. The introduction of strong 
noncovalent bonding such as ionic and H-bonding interactions between the potential 
small-molecule inhibitors and the PPI targets becomes an exciting and important research 
direction for the discovery of potent PPI inhibitors, in particular considering many PPI 
interfaces are shallow, hydrophobic, and require low desolvation penalty. The current 
drug design strategies for introducing ionic functional groups and/or H-bond donors and 
acceptors cannot overcome the low desolvation penalty requirement to bind shallow PPI 
interfaces. 
To further explore the relationship between inhibitor potency and burial, we 
examined the Bcl-XL/BH3-domain PPI, another important therapeutic target. In contrast 
to the MDM2 crystal structure inhibitor study, a specific series of Bcl-XL inhibitors with 
the variations on the designated side chains was chosen for this study.71 As shown in 
Figure 3.6, the property θl was found to be correlated with the Ki values of the Bcl-
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XL/BH3-domain inhibitors. Furthermore, Bcl-XL is known to have a flexible interaction 
surface, a structural feature of many PPI targets. Therefore, the result in Figure 3.6 
indicated that θl could be used to assess the potency of PPI inhibitor derivatives. This 
result also echoes a previous study that found most nonfragment inhibitors which are 
structurally similar bind in similar fashion.79 
Next the effect of ligand burial on HTVS was evaluated, confirming similar 
observations from Gowthaman et al.24,25 that current virtual screening programs were ill-
suited for docking PPI inhibitors. The ability of the common docking programs to 
determine a proper pose and to identify potent PPI inhibitors from a series of putatively 
inactive compounds was evaluated. The inhibitor-bound protein complexes were chosen 
for this study because they are all examples of highly potent inhibitors bound to a PPI 
interface. It was found that AutoDock Vina was more accurate in delivering a valid pose 
with lower rmsds from the biologically active conformations in the crystal or NMR 
structures. However, AutoDock Vina was less effective at scoring the known inhibitors 
relative to the putatively inactive compounds. In contrast, Glide more often identified the 
known inhibitors, but generated less than optimal predicted poses. One possible 
explanation for these results could be the differences of the docking algorithms and the 
scoring functions used by the two programs. AutoDock Vina uses a Lamarckian genetic 
algorithm to dock the ligand and a knowledge-based scoring function to rank the poses. 
This knowledge-based scoring function was originally proven using traditional targets, 
not PPI targets, when it was developed.78 Glide fared better at scoring known inhibitors, 
but produced inferior poses. It was unclear if increasing the number of poses produced by 
Glide SP would have aided in pose prediction, but only the top picks are usually assessed 
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in virtual screening. AutoDock Vina uses a machine learning scoring function, described 
by Trott and Olson,78 as opposed to the empirical scoring function used by Glide and 
Gold. The empirical scoring function may be more appropriate for PPIs because it is 
more physics-based. Success in HTVS is to not only identify a potential hit but also to 
produce a valid binding pose that could be used to guide further inhibitor optimization. 
Therefore, the AutoDock Vina poses were rescored using Glide SP score-in-place, with 
the belief that the empirical scoring function would be better at identifying known 
inhibitors. As expected, the poses predicted by AutoDock Vina and rescored by Glide 
gave better results for two docked ligands, 3UR4 and 4ERF. As observed by Trott and 
Olson,78 the Lamarckian genetic algorithm for docking was able to more accurately 
predict the poses for the known ligands. However, the one success of AutoDock Vina, 
1TFT, was ranked worse with Glide rescoring. The MM/GBSA reranking was overall no 
more effective than Glide rescoring of the AutoDock Vina poses. In some cases, 
MM/GBSA reranking was worse. The results of the HTVS study suggested that an 
empirical scoring method for ranking potential hits might improve results, but neither 
rescoring using different scoring functions nor the computational estimates of binding 
energy by MM/GBSA were sufficient to identify potent PPI hits.  
Lastly, the relationship of θl to the different docked poses of the same ligand was 
examined using AutoDock Vina. A moderate-to-strong correlation was observed for each 
of the five PPIs, indicating that the docking program better scored the poses that were 
more deeply buried (Figure 3.7). The property θl alone cannot rank HTVS hits because it 
is secondary to the strong noncovalent interactions. Regardless, given the evidence from 
Gowthaman et al.20 and the studies presented here, it would be wise to consider θl as an 
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adjunct property when selecting hits from an HTVS. A more buried ligand will provide a 
better starting point for inhibitor development because it can more efficiently use the 
limited space available in PPI pockets, some of which contain hot spots. 
 
3. 5 Conclusion 
PPIs represent a class of appealing drug targets where conventional methods for 
drug discovery have been met with difficulty. This is due to the nature of the PPI 
interface which contrasts in size and shape with traditional drug targets. One way to 
overcome these problems is through the use of hot spots,8-10 or the regions in the PPI 
interface that contribute more to binding energy. HTVS has had moderate success at 
finding hits for PPIs; however, most of these hits were typically discovered with the aid 
of other methods and exhibited low potency. Two critical components need to be 
assessed in HTVS: correctly ranking hits with good potency, and predicting a valid pose 
which can be optimized further. This evaluated the ability of two common molecular 
docking programs with distinct docking and scoring algorithms to identify known, highly 
potent, small-molecule inhibitors for PPIs. It was found that the choice of scoring 
function is important when ranking HTVS results, and the use of MM/GBSA calculated 
ΔΔGbinding to rerank inhibitors was met with mixed results. The study evaluated an 
additional property, θl, which is relevant to all small molecule–protein interactions, but 
addresses specific challenges in inhibiting PPIs, such as low ligand efficiency due to 
shallow binding surfaces. This property relates with the efficiency of ligand burial and, 
therefore, with hot spots. θl shows a positive correlation with IC50 or Ki when examining 
known inhibitors for the MDM2/p53 and Bcl-XL/BH3-domain PPIs. While no effect of θl 
   121 
 
on reranking docking results was observed, this could be due to the strong non-covalent 
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EVOLUTIONARY TRACE AND SEQUENCE ANALYSIS  
REVEAL INSIGHTS INTO CATENIN-LIKE PROTEINS,  
IMPLICATIONS FOR DRUG DESIGN, SELECTIVITY,  
AND POTENTIAL FORALLOSTERIC REGULATION 
 
4.1 Introduction 
The PPI between the ARM domain protein β-catenin and Tcf4 is a promising, yet 
elusive, drug target.1 This PPI is the penultimate step in the Wnt signaling pathway where 
it mediates the formation of a nuclear transcription complex.2 The canonical Wnt 
signaling pathway is responsible for the expression of Wnt target genes that are important 
for stem cell differentiation and survival.3 Mutations in proteins associated with canonical 
Wnt signaling4,5 result in the dysregulation of the Wnt signaling pathway, accumulation 
of β-catenin, and the untimely overexpression of Wnt target genes. Mutations in APC, a 
protein responsible for sequestering excess cytosolic β-catenin for degradation, are 
present in most cases of sporadic colorectal cancers.6 Other mutations in Wnt-associated 
proteins have been identified in cancerous skin stem cells,7,8 oral cancer,9,10 and 
numerous others.5,10 Inhibiting the formation of the β-catenin/Tcf4 downstream nuclear 
complex represents a way to disrupt the aberrant Wnt target gene expression and halt 
cancer stem cell renewal.1 Unfortunately, β-catenin is a promiscuous protein with over 
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one hundred direct binding partners.11,12,13 Several proteins, E-cadherin,14 APC,15 axin16 
and Tcf17, are known to bind to a long, positively-charged groove that runs the length of 
the ARM domain of β-catenin.  β-catenin functions as a structural protein by binding to 
E-cadherin at adherens junctions;18 axin and APC mediate cytosolic β-catenin levels by 
sequestering excess β-catenin for degradation in the destruction complex.19,20 Crystal 
structures for β-catenin/Tcf (PDB IDs 1JPW,21 1JDH,22 2GL7),17 β-catenin/E-cadherin 
(PDB IDs 1I7X,14 1I7W)14 and β-catenin/APC (PDB IDs 1TH1,15 1JPP,23 1T08)24 reveal 
three shared hot regions on the ARM domain of β-catenin.25,26 These hot regions are 
surface areas where residues contribute significantly greater to binding energy than the 
surrounding residues. Hot region 1, with K435, forms the binding site of the DxθθxΦx2-
7E motif of E-cadherin, APC and Tcf4 (Figure 4.1).21,22,25,27This hot region is the most 
important of the three hot regions for binding Tcf4,22 even though E-cadherin and APC 
both share a similar binding mode. Hot region 2 contains K312, K345, and Y306. Hot 
region 3 contains residue R212 and is important for binding axin, in addition to Tcf4, E-
cadherin, and APC.26 In addition to the three hot regions, β-catenin contains a separate 
binding site near the N-terminal region of the ARM domain for Bcl9, another component 
of the nuclear transcription complex.17 
E-cadherin and APC also utilize phosphorylation to enhance their binding to β-
catenin.14,15 Residues T1487, S1504, S1505, S1507, and S1510 of APC are capable of 
being phosphorylated, as are residues S684, S686, S690, and S692 in E-cadherin. These 
phosphorylated residues interact with K292, K335, and R376 of β-catenin.26 Tcf4 does 
not undergo phosphorylation; therefore, it relies less on these residues. While β-catenin 




Figure 4.1. Binding mode of Tcf4, APC, and E-cadherin in β-catenin hot region 1. 




function and binding.28,29 β-catenin is one member of the large family of ARM domain 
proteins. The armadillo repeat motif that defines this family consists of two α-helices 
forming a hairpin-like structure30,31 that is repeated to form the ARM domain. These 
proteins compose a functionally diverse, yet structurally similar, family of proteins 
responsible for cellular signaling, adhesion, and structural networks.31,32 The ARM 
family of proteins includes such notable members as β-catenin, plakoglobin (JUP, γ-
catenin), APC, and importin.33 A subset of these ARM proteins has functional overlap 
with β-catenin. These catenin-like proteins include JUP in humans, and symmetrical 
sister cell hermaphrodite gonad defect 1 (SYS-1), humpback 2 (HMP-2), armadillo repeat 
domain containing WRM-1 and β-catenin/armadillo-related protein 1 (BAR-1) in C. 
elegans.28,29 Sequence similarity between catenin-like proteins ranges from very high, 
between plakoglobin and β-catenin,34 or very low, between SYS-1 and β-catenin.30 
Consequently, these proteins are identified by armadillo repeat structural motif and 
function rather than primary sequence identity.29,35 
The most closely related ARM family member to β-catenin is JUP, which shares 
64% sequence identity overall and 79% sequence identity in the ARM domain.34 All the 
important lysine residues are conserved, as are the residues that interact with the 
DxθθxΦx2-7E motif of Tcf4, APC and E-cadherin,36 and the residues responsible for 
binding the pS/pT-motif of APC and E-cadherin.29 Despite this similarity, JUP has a 
more specialized function. JUP is a key structural protein of the desmosome, linking 
desmosomal cadherin proteins to desmoplakin.34 Unlike β-catenin, which is found in both 
the cytosol and nucleus, JUP is predominantly localized to the desmosome and has a 
higher affinity for desmosomal cadherins than the E-cadherin found at adherens 
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junctions.36 Although JUP binds to Tcf4 in biochemical assays, the interaction with DNA 
is considerably weaker than that of the β-catenin/Tcf4 complex.36 
The four other types of catenin-like proteins, SYS-1, HMP-2, WRM-1, and BAR-
1, are found almost exclusively in the genus Caenorhabditis, but not in other 
organisms.28,29,37 These proteins are specialized in function unlike the promiscuous β-
catenin even though they share similar structures and key residues. These specialized 
divergent catenins have only minimal sequence identity with β-catenin (full 
sequence/ARM domain): BAR-1 (22%/24%), HMP-2 (27%/31%), WRM-1 (16%/18%), 
and SYS-1 (12%/14%). 
BAR-1 is the closest homologue in function, if not in sequence, to human β-
catenin found in C. elegans.28 BAR-1 fills β-catenin’s role in canonical Wnt signaling. 
Homology modeling of BAR-1 indicates that it binds the C. elegans Tcf4 homologue 
POP-1 in a similar manner as β-catenin binds Tcf4.28 BAR-1 has less conservation in hot 
regions 2 and 3 and does not interact with HMR-1, the C. elegans homologue of E-
cadherin. HMP-2, by contrast, does not interact with POP-1. Instead, HMP-2 interacts 
with hammerhead cadherin-like protein HMR-1 in a manner similar to that of β-catenin 
and E-cadherin.28,29 HMP-2 contains the key residues responsible for binding POP-1, but 
a nearby mutation may compromise the function of the K365 (β-catenin K435) hot 
spot.28,29 WRM-1 interacts with neither POP-1 nor HMR-1. WRM-1 binds to 
Serine/threonine nemo-like kinase LIT-1 to inhibit POP-1 transcription.28,29 The hot spot 
K497 (human β-catenin K435) is conserved, but the bulky side-chain of WRM-1 L491 
blocks POP-1 E9 (human Tcf E17) access to this residue. SYS-1 is the most recently 
identified catenin-like protein.29 The sequence similarity between β-catenin and SYS-1 is 
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considered insignificant, and it was not until a crystal structure of SYS-129 was produced 
that it was verified as a member of the catenin-like protein family. SYS-1 interacts with 
the Caenorhabditis Tcf4 homologue POP-1 to regulate gene transcription specific to 
producing asymmetrical daughter cells in C. elegans, but is not involved in canonical 
Wnt signaling.29,35 The salt bridge between K539 of SYS-1 and D8 of POP-1 (K435 and 
D15 in human β-catenin and Tcf4) is conserved, but the other salt bridges found between 
β-catenin and Tcf4 are not present in the SYS-1/POP-1 crystal structure (PDB ID 
3C2G).30 Regardless, SYS-1 was able to rescue Wnt signaling in BAR-1 null mutants 
when attached to a BAR-1 promotor region.29,35 
While much study has been conducted on β-catenin and its binding partners, 
much remains to be understood about the differences between catenin-like proteins, 
binding-partner selectivity, and druggability. This is important because one of the biggest 
hurdles for disrupting the β-catenin/Tcf4 PPI is the risk of disrupting the β-catenin/E-
cadherin and β-catenin/APC PPIs.1 Clues about designing selective small-molecule 
inhibitors can be garnered from examining the differences between the different C. 
elegans catenin-like proteins. One lysine hot spot in hot region 1 (K435 in human β-
catenin) is universally conserved between human β-catenin and JUP and the C. elegans 
catein-like proteins.29 It is also the most important residue for interaction with Tcf4 and 
its C. elegans homologue POP-1, yet not all catenin-like proteins possess the ability to 
bind Tcf4/POP-1.27-29 There is evidence that E-cadherin and APC, while binding 
similarly to K435 region of β-catenin, rely more on K292, K335 and R376.27 These three 
residues are conserved in HMP-2 (K220, K264 and R306, respectively) whichs binds the 
C. elegans cadherin homologue HMR-1, but are not conserved in SYS-1 nor WRM-1 
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which do not bind HMR-1.28,29 Furthermore, residues K292, K335 and R376, which are 
responsible for binding the pS/pT-motif of E-cadherin and APC,27 are conserved in 
HMP-2. By exploiting these differences, the Ji lab succeeded in creating potent, selective 
inhibitors of the β-catenin/Tcf4 interaction.38,39 However, much about the selectivity and 
differences in catenin-like proteins remains to be explored.  
In this study, ET analysis is used to predict and rank functionally important 
residues. It has also been used to identify previously unknown allosteric sites. ET was 
used to identify a novel allosteric site in the D2 dopamine GPCR.40 It is hypothesized that 
the inclusion of JUP and the four specialized C. elegans catenin-like proteins in ET 
analysis will yield important information as to the varying importance of the hot regions. 
ET may also be useful in discovering latent allosteric sites which can be used to 
selectively inhibit the β-catenin/Tcf4 interaction. 
ET can help identify functionally important residues and potentially allosteric 
regions, but lacks data about the druggability of said residues. In order to assess the 
druggability of the differing hot regions, FTMap, a solvent mapping program developed 
by Kozakov et al.41-44 is used. Because β-catenin has multiple binding partners binding to 
the same hot regions, solvent mapping different crystal structures may give insight into 
surface adaptability and the origin of selectivity. β-catenin was reported to be a flexible 
protein,45 so an MD simulation was utilized to further explore the druggability of β-
catenin. Combining FTMap with the MD simulations provided a way to analyze 
druggability changes in the three hot regions throughout the simulation. This unique 
combination of computational approaches has yielded new insights into the similarities 
and differences of catenin-like proteins and lead to the discovery of a new potential 
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allosteric site for regulating the β-catenin/Tcf4 PPI. 
 
4.2 Methods 
4.2.1 FTMap analysis.  FTMap solvent mapping analysis was conducted on 
crystal structures 1TH1,15 1QZ7,16 1I7X,17 and 2GL718 with ligands removed and MD 
trajectory snapshots of cluster centroids. Calculations were carried out using the FTMap 
web server with parameters specific for PPIs.43 To facilitate comparison of probe 
interactions on a per residue level, the total number of probe interactions was normalized 
to a percentage. Because other nonbonding (van der Waals) interactions always 
outnumbered hydrogen bond interactions, they were also normalized in a similar manner. 
Results were analyzed and visualized using Sybyl,46 R software47 (GGPlot2,48 
Reshape2)49 and UCSF Chimera.50 
4.2.2 Evolutionary trace analysis.  Primary sequences of β-catenin, plakoglobin 
(including γ-catenin), WRM-1, SYS-1, HMP-2, and BAR-1 were obtained from 
UniProt.51 Accessions with greater than 90% sequence identity to human β-catenin 
(UniProt accession P35222) were discarded. Forty-nine sequences were included for the 
multiple sequence alignment (MSA) and subsequent ET analysis. The sequences were 
aligned using the ClustalOmega web server.52,53 The sequences were trimmed so that 
only residues aligning to the ARM domain of human β-catenin were included in the ET 
analysis. Real-value ET (rvET) scores were calculated by the web server provided by the 
Lichtarge computational biology lab at Baylor College of Medicine.54 rvET output data 
was analyzed with R software48 and Schrödinger Maestro.55 Unless otherwise noted, the 
residues discussed are all in reference to human β-catenin (PDB ID 2GL7)24.  
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4.2.3 Molecular dynamics simulations.  A β-catenin construct consisting of the 
main ARM domain of human β-catenin (PDB ID 2GL7,17 residues 147-549 and 560-
663), and the missing loop and C-terminal helix 12 (PDB ID 2Z6H,56 residues 550-559 
and 663-686) was created with Sybyl Biopolymer.46 The construct was minimized by a 
5000-step method in Schrödinger Macromodel.57 The topologies for the simulation were 
generated with Gromacs58 using the AMBER03 force field.59 Simulations were 
conducted in a dodecahedron solvated with TIP3P water molecules, and ions were added 
to neutralize the system. The system was energy minimized by a 5000-step steepest 
descent method until the maximum force in the system (Fmax) is less than 1000 kJ mol
-1 
nm-1. Next, the system was subjected to NVT ensemble (constant number of particles, 
volume, and temperature) and NPT ensemble (constant number of particles, pressure, and 
temperature) equilibrations of 100 ps each while all nonsolvent heavy atoms were 
restrained. MD simulations were conducted using Gromacs for 20 ns at 310K. The 
trajectory was clustered by RMSD using the GROMOS60 algorithm. Four groups were 
used for RMSD calculations, all protein heavy atoms, and hot regions 1-3. The following 
residues were used as definitions of the hot regions: hot region 1 contains residues G422, 
S425, N426, L428, C429, N430, K435, E462, P463, I465, C466, R469, H470, S473, 
R474, Q482, L506, I507, K508, A509, V511, G512, R515, N516, L519, L536, L539, 
R565, E568, I569, E571, G572, C573, G575, A576, H578, I579, R582, N609, R612, 
V613, E620, Y654; hot region 2 contains residues Q302, I303, A305, Y306, G307, G307, 
N308, Q309, S311, K312, I315, T332, Y333, E334, K335, L336, L337, W338, T339, 
S341, R342, V343, K345, V346, L347, S348, V349, C350, S374, Q375, R376, L377, 
V378, N380, T384; hot region 3 contains residues V173, V175, H176, Q177, S179, 
141 
 
A211, R212, C213, A215, G216, T217, H219, N220, S222, H223, H224, K242, D249, 
S250, F253, Y254, A256, T257, T258, L259, H260, N261, L264, H265, T289, N290, 
V291, K292, FA293, L294, A295, I296, T297, D299.  
4.2.4 Fluorescence polarization binding assay of β-catenin mutants.  Three β-
catenin point mutants, W504A, W504L, and W504I, were created using overlapping 
PCR. Proteins were expressed using transformed BL21 E. coli cells and purified by Ni-
NTA column. The proteins were dialyzed overnight at pH 8.8. Protein purity was verified 
using SDS-PAGE. Protein concentration was measured through a colorimetric Bradford 
assay. The effect of the point mutations on β-catenin/Tcf binding was determined through 
fluorescence polarization using a Tcf4 fluorescence tracer (excitation wavelength = 485 
nm, emission wavelength = 535 nm). Wild-type β-catenin and Tcf4 tracer was used as a 
negative control, and Tcf4 tracer alone provided a positive control. Kd values were 
calculated using GraphPad Prism 5 software using a nonlinear least squares analysis. 
 
4.3 Results 
4.3.1 FTMap of crystal structures.  Solvent mapping of the β-catenin/Tcf4/Bcl9 
crystal structure (PDB ID 2GL7)17 places five of the nine total probe cross-clusters in hot 
region 1, and one cross-cluster in hot region 2. When probe interactions were examined 
on a per residue basis, no single residue in hot regions 2 or 3 had more than 2% of the 
total solvent probe interactions in a single category (hydrogen bonds or other nonbonding 
interactions).  In contrast, hot region 1 contained residues that had upwards of 10% of the 
total solvent interactions in either category. β-catenin structures with E-cadherin bound 
(1I7X)14, APC bound (1TH1)15 and axin bound (1QZ7)16 were also evaluated for surface 
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changes affecting druggability (Figure 4.2). Hot region 1 maintained dominance in all the 
tested crystal structures, but increases in the number of probes at hot regions 2 and 3 were 
observed. The crystal structure with E-cadherin bound showed an increase of 10% in hot 
region 2 and 3% in hot region 3, while a decrease of 5% in hot region 1 compared to 
2GL7. The crystal structure of axin bound β-catenin showed an increase of 4% and 9%, 
and a decrease of 13%, respectively. The phosphorylated APC bound crystal structure 
showed an increase of 2% and 18%, and a decrease of 22%, respectively. This is 
evidence of surface flexibility and surface adaptability of hot regions 2 and 3 in the 
presence of different binding partners. In order to further explore the importance of the β-
catenin hot regions, ET analysis was performed on β-catenin and catenin-like proteins. 
4.3.2 Multiple sequence alignment.  The multiple sequence alignment of 49 β-
catenin, JUP, SYS-1, HMP-2, WRM-1, and BAR-1 amino acid sequences from UniProt51 
indicate no residues are entirely conserved between species. Most hot regions have a high 
degree of conservation, but differences occur between different proteins and different 
species. This was surprising because even K435 was not entirely conserved in these 
sequences as previously thought. These differences in sequences between catenin-like 
proteins likely correspond to differences in function as observed in the Caenorhabditis β-
catenin homologues.  
4.3.3 ET analysis.  ET analysis reports results as real-value ET scores (rvET); a 
lower score is indicative of a potentially more functionally important residue54. A full list 
of rvET scores may be found in the appendix of this chapter.  Key residues in all three 
hot regions along the groove of β-catenin have low rvET scores. This indicates that ET 





Figure 4.2.  Probe interactions from solvent mapping the different crystal structures of β-
catenin. Interactions in crystal structure 2GL7 are almost entirely located in hot region 1. 
The other hot regions have more probe interactions when other binding partners were 
present in the crystal structure. Interestingly, hot region 1 maintains a large amount of 
interactions even in 1QZ7, in which nothing was bound to hot region 1. This may 
indicate that while hot regions 2 and 3 are only accessible in the presence of a binding 
partner, hot region 1 is accessible when nothing is bound. 
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analysis confirms the importance of known hot-spot residues (Figure 4.3). Of the key 
lysines in the main groove of β-catenin, K312, 345, K435, and K508, K435 is ranked as 
the most evolutionarily important (rvET = 2.64), and K312 was the least important (rvET 
= 7.43) of the three key lysine residues. This is reflection of the conservation between the 
different variants of catenin-like proteins. Of the three known hot regions, hot region 1 
showed the most evolutionary importance.  
Few residues outside of the long positively-charged groove of the ARM domain 
had low rvET scores. Surprisingly, this extended to the N-terminal Bcl9 binding region. 
Reasons for this may be that it is not conserved in the worm β-catenin variants or that 
Bcl9 is dispensable in Wnt signaling.61 One exception, residues which have very low ET 
scores but are not part of the surface of β-catenin, were the leucine residues scattered 
throughout the interior of the protein. This is expected due to the similarity of the 
armadillo repeat to the leucine-rich repeat motif in other alpha-solenoid structures.62,63 
Another exception was a region centered on W504 of human β-catenin (Figure 4.4). 
W504 itself had a low rvET score of 4.80, which was lower than K312 and K508. 
Surrounding it are residues H503 (7.01), P505 (4.29), R542 (5.80), and E562 (5.06). 
Disappointingly, FTMap did not indicate that this would be a druggable site in any of the 
tested crystal structures. An attempt was made to find alternative conformations of this 
pocket, which may be druggable, by MD simulation. 
PPI surfaces are well known to be flexible, and β-catenin was reported to be a 
flexible protein in previous MD studies.45 The β-catenin construct from the crystal 
structures 2GL7 and 26ZH was created so that the most complete structure of the ARM 





Figure 4.3. The ET results are visualized on the β-catenin crystal structure 2GL717 (left). 
Residues with the lowest rvET scores are colored red. Those higher are orange and 




Figure 4.4. The region surrounding W504 has residues which are potentially functionally 
important. Tcf4 (teal) does not interact with this region. The number of residues in this 
area that could be functionally important leads us to the conclusion that this site may be a 




ARM domain of β-catenin. RMSD clustering of the MD simulations on protein heavy 
atoms with a 2Å cutoff found 53 clusters. The top 20 centroids of these clusters, which 
represent 90% of the simulation snapshots, and the initial 2GL7/2Z6H construct were 
analyzed with FTMap. The number of probe interactions was normalized between 
interaction types, because nonbonding interactions always outnumbered hydrogen 
bonding interactions. Then it was normalized between different protein structures. The 
changes in probe interactions per residue compared to the starting structure (Δprobes) 
were examined to detect changes in druggability throughout the simulation (Figure 4.5). 
Changes in Δprobes were classified in three categories: those which occurred within the 
main binding groove of β-catenin, those which occurred outside of the main binding 
groove of β-catenin with high rvET scores (rvET > 7), and those which occurred outside 
of known binding surfaces that had low rvET scores (rvET < 7). The analysis of the MD 
simulation showed several areas of the structure with increased druggability in the 
simulation as compared to the crystal structure in the first category. These were certain 
areas of the hot region 1 (Figure 4.6) which showed more probe interaction in simulation 
structures than the crystal structures. These subtle changes in side-chain orientation 
revealed alternative conformations of this hot region that could be used for drug 
discovery. Similar results were seen in hot region 2, hot region 3, and the W504 pocket 
(Figures 4.7-4.9). 
In the third category was the region near W504, a region previously identified as 
potentially functionally important in ET analysis. This residue showed no probe 
interactions in the initial crystal structure FTMap analysis. However, FTMap cross-





Figure 4.5. Comparison of probe changes from clustering all β-catenin heavy atoms. Red 
regions represent an increase in probe interactions; blue regions represent a decrease in 
probe interactions. The green box represents probe interactions that are occurring in the 
















Figure 4.9. Comparison of probe changes from clustering the W504 site heavy atoms. 
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When taken together with the ET results, this pointed to the W504 site as a potential 
allosteric site. In order to probe for allostery between the W504 site and nearby hot 
region 1, a traditional alanine mutant and two mutants where the W504 side-chain was 
replaced with a bulky leucine or isoleucine side-chain were created. The intent with the 
latter two mutants was to mimic small-molecule binding. FP assays on β-catenin mutants 
were performed with labeled Tcf4 to test for changes in binding affinity. The results 
showed a modest increase in the ability of the W504I and W504L mutants to bind Tcf4, 
but no change in the W504A mutant (Figure 4.10). The W504I mutant decreased the Kd 
of the β-catenin/Tcf4 interaction from 2.3 nM to 0.72 nM. The W504L mutant decreased 
the Kd of the β-catenin/Tcf4 interaction to 1.3 nM. The W504A mutant remained 
unchanged at 2.1 nM. It was concluded that if allosteric modulation were achievable at 
this site, it would be by interaction with a bulky binding partner(s). 
 
4.4 Discussion 
The results from a combination of ET analysis, FTMap solvent mapping and MD 
simulations revealed important clues about the origins of catenin-like protein binding 
partner selectivity. Previous work on β-catenin inhibitors showed that hot region 1 is 
most important for the interaction involving Tcf4,27 and the results from this study 
confirmed it. Hot regions 2 and 3 had residues with higher rvET scores, which is in line 
with research that indicated other binding partners, E-cadherin, APC and axin through 
phosphorylation.23,24 This supported the notion that by altering the three hot regions, 
Caenorhabditis catenin-like proteins achieved specificity.  





Figure 4.10. FP assay results of β-catenin point mutants. The W504A mutation showed 
no difference in Tcf binding. The W504I and W504L mutants bound Tcf4 more tightly. 
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importance and interactions of the three hot regions as well as hot region surface 
flexibility between binding partners when the different crystal structures were solvent 
mapped. In the Tcf4 bound crystal structure (PDB ID 2GL7), most of the solvent 
interactions were found in hot region 1, the hot region most important for binding Tcf4. 
The 1TH1, 1QZ7, and 1I7X structures were crystalized with binding partners that rely 
more on hot regions 2 and 3.27 As expected, the number of probe interactions in these 
three structures in hot regions 2 and 3 increased, giving further evidence that these hot 
regions are more important for these binding partners than Tcf4.  
MD simulations were used to reveal surface residue conformations that were not 
seen in other crystal structures. The combined use of FTMap and MD simulations were 
used in the past to reveal novel computational hot spots for drug design.43 This was taken 
one step further by comparing the FTMap data to Evolutionary Trace scores in an attempt 
to identify novel allostery at potentially drugabble sites. A region near hot region 1 
centered on residue W504 was identified as a potential novel allosteric site, because it did 
not contact Tcf4, E-cadherin, nor APC. It was first identified with ET analysis; however, 
it was not apparent that this region was suitable for binding a small molecule. By 
clustering the MD simulations based on the heavy atoms of the ARM domain and solvent 
mapping the representative structure, it was found that the conformation of this pocket 
may shift to one that is druggable and more accessible to FTMap probes. Because no 
known binding partners used this site, bulky amino acid side chains isoleucine and 
leucine were used to mimic a binding partner.  The observed changes in Tcf4 binding 
were small, but the mutation was limited to a single residue with no known contact to 
Tcf4. Therefore, it was concluded that the potential for allostery between this site and the 
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nearby hot region 1 may be possible. 
 
4.5 Conclusion 
The β-catenin family of proteins, β-catenin, JUP, SYS-1, HMP-2, WRM-1, and 
BAR-1, fill important roles for cell development, differentiation, and adhesion.1,32 The β-
catenin interaction with Tcf4 is an important drug target because of its role in the 
canonical Wnt signaling pathway; the dysregulation of which is involved in many cancers 
and fibroses.32 The downstream disruption of the canonical Wnt signaling pathway by 
inhibiting the β-catenin/Tcf4 PPI provides a means of disrupting cancer stem cell growth 
and division. This target is challenging due to the shared binding surface on β-catenin 
with Tcf4, APC, and E-cadherin. This study provided insights into achieving selectivity 
for the β-catenin/Tcf4 PPI, over the β-catenin/APC, and β-catenin/E-cadherin 
interactions. Solvent mapping by FTMap confirmed that Tcf4 relies heavily on hot region 
1, while E-cadherin and APC utilize hot regions 2 and 3 in different surface 
conformations. Evolutionary Trace analysis of β-catenin, JUP, BAR-1, HMP-2, WRM-1, 
and SYS-1 revealed the origins of β-catenin binding partner selectivity and was able to 
discover a novel allosteric site near hot region 1. This novel allosteric site, centered on 
W504, did not have any interaction with probes from FTMap. However, when molecular 
dynamics simulations were conducted to reveal new FTMap hot spots not present in the 
analyzed crystal structures, several cluster centroids revealed probe interaction with 
W504 and the surrounding residues. W504 mutant β-catenin was tested for its ability to 
bind Tcf4 in order to confirm the presence of allosteric regulation between W504 and hot 
region 1. W504I/L mutant β-catenin proteins showed a mild positive allosteric effect on 
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Tcf4 binding in an FP assay. This unique combination of computational approaches has 
yielded valuable data from which better selective inhibitors of the β-catenin interaction 
may be designed. 
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4.7 Supplementary materials of real-value  
evolutionary trace scores 
 
Table 4S.1. Full list of ET scores 
Residue Variations rvET scores Residue Variations rvET scores 
D144 IVRE.GDCSN 8.26 C429 AIHLCS 3.83 
D145 RKN.QSED 8.08 N430 HSGNQ 3.45 
A146 QRPSAH.YNTK 12.06 N431 KMPNH 3.81 
E147 DEVC.NIA 7.83 Y432 QLESKGRVTPHAIMY 16.85 
L148 FLSTM.EAVI 11.12 K433 HP.LTMARNEYKQWS 11.75 
A149 AVNQ.TGS 9.22 N434 VN 1.32 
T150 QNTALMR.VKEG 12.93 K435 KVTC 2.64 
R151 VIDGR.SNYEQTKFL 11.85 M436 DEATFQKLSIYVM 17.83 
A152 NQETAS.GV 8.93 M437 ILKRAEFHSTVMQ 17.02 
I153 MLYNHI.VAS 10.53 V438 AFVMLT 6.2 
P154 PWSQ.E 5.95 C439 IQYSVACFHT 8.85 
E155 QRHDE.KNL 9.46 Q440 RAGENQSKF 10.91 
L156 ILV.FA 6.67 V441 SKNYLARMFCHV 16.83 
T157 LQKRIC.VTASP 12.34 G442 NGKRHMSA 12.69 
K158 NLKQD.MHRESG 11.32 G443 AGVR 3.92 
L159 ILAFSNQ.H 6.53 I444 ILHVTM 8.64 
L160 IVLM.T 5.91 E445 FPGESDVMTQ 10.08 
N161 YHKRATS.NIGCQ 15.43 A446 LTQIHNARSGV 9.85 
D162 DNESA.GHQ 7.53 L447 LAVI 3.61 
E163 GQETDSANK.VPH 9.89 V448 HCVILSMY 9.6 
D164 LMTDEGKN.S 7.81 R449 TDKRGQHASC 12.27 
Q165 PAVTY.ENQSL 11.56 T450 IVTLQAMC 12.48 
V166 QTVSRAED.NML 11.6 V451 ILVC 6.29 
V167 PQVICTE. 9.84 L452 .FNQKSRCLGEAITMYV 13.96 
V168 VILHQTS.C 9.9 R453 .TVSDEQLNIRKAH 12.02 
N169 QTAEYHVD.NKSGLM 15.56 A454 .TNYARHSQPICGFL 13.53 
K170 LTFSVNKRQ.EH 12.02 G455 .NDGQLEPVIYATS 11.47 
A171 SACT.V 7.82 D456 .QSIVRDEGAFTN 12.43 
A172 YASTIV. 10.4 R457 .PCRIMSVKQL 9.94 
V173 YMLRAITKQ.SVH 11.05 E458 .EPDLQFAG 8.19 
M174 .FMRCGEYLHVIT 13.37 D459 .ERSD 5.87 
V175 .QDLMVAI 8.18 I460 SMVTAI.Y 10.59 
H176 APFSEQYH.N 10.42 T461 KRLVY.QTAFIS 9.55 
Q177 QNSPHAM.GDEKRL 9.17 E462 YSVAE. 4.01 
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Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
L178 LMPIV. 6.02 P463 PTN.CSR 5.61 
S179 WYMASC.T 9.77 A464 RPVSTC.LAIG 8.75 
K180 YCQVTKR.NH 9.25 I465 LVAC.IM 7.24 
K181 NYEDKM.TSR 10.64 C466 DSGAC. 5.82 
E182 L.FWKGDEQVN 8.97 A467 EDAGTVIPC 9.59 
A183 LTISACGP.K 8.14 L468 LFR 2.96 
S184 DCSLEA.FN 6.34 R469 TANGPLKR 7.15 
R185 IQKENHPRTM.LCFV 9.57 H470 DEINKH 5.45 
H186 FSQLVAIDE.HTMKRYN 15.78 L471 AGFLMVHSIC 8.5 
A187 LYAQSTRP.GN 7.91 T472 PSYATCN 5.64 
I188 PRIYML.VTA 9.45 S473 KQGTLSVAHYC 9.53 
M189 ITRFGAQ.VLNMP 10.05 R474 RK.MGN 4.91 
R190 ITDESCVRANK.GQ 13.36 H475 NK.SADH 6.13 
S191 SIAVNLCGDTY.H 11.67 Q476 RL.QPEASGHDVN 14.33 
P192 PGKQASTIFRM.NH 12.96 E477 VA.NQSYMHLEDFG 12.75 
Q193 YNGLQERKD.AVS 14.82 A478 C.DIASQYEV 6.27 
M194 .ILVMAF 8.29 E479 EGIDQPVSNA 9.86 
V195 ILVA. 7.36 M480 IPESQKDATMRVLHNF 12.41 
S196 HEPDRTAFSKGLQN 12.87 A481 IVAPGETC 7.7 
A197 QLVPATHEGC 10.86 Q482 CSNILVRQE 10.55 
I198 VILM 6.18 N483 NKRHTSAYD 8.45 
V199 VIFLRKAMC 9.69 A484 CSAMHFEITDG 13.58 
R200 QNKEVDRHSGA 13.76 V485 LIVACMF 8.56 
T201 MLCVKTA 10.03 R486 RLQDAIH 6.82 
M202 FLV.IMTA 7.9 L487 TAKSGMDVQHELNIF 11.98 
Q203 P.SRDTQVINGEA 12.99 H488 LMCAHKIG.EDQSFNT 15.3 
N204 RKDSTLNHMAQ 13.26 Y489 NGS.FPQAYH 9.59 
T205 EGTSVCAINFL 11.4 G490 NGAVES.TL 5.82 
N206 NDEPSVGRHKTAQ 16.34 L491 FIVNLSPA. 7.51 
D207 GQEDHSN 7.98 P492 LKPQTSRAE. 8.56 
V208 PQVEDINKASLMG 16.44 V493 MSPADLF.TNIV 10.01 
E209 QYHKDNEASR 10.99 V494 MILSDF.V 8.27 
T210 DECVILTAS 9.76 V495 WVLAT.SIMC 7.02 
A211 FKQILVETMAR 10.85 K496 IDNEHAR.SVK 11.42 
R212 RIKHNAS 8.07 L497 PLVISRK.FQ 7.79 
R212 RIKHNAS 8.07 L497 PLVISRK.FQ 7.79 
C213 EDGNKFVPCYSA 13.73 L498 TMLV.I 5.02 
T214 LSTACIV 8.48 H499 PQTKLSY.REHNDAC 13.21 
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Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
A215 ILVFCSATQG 12.54 P500 NTQ.PM 6.64 
G216 CKEGLSA 5.41 P501 GN.PTEDAVQLS 6.97 
T217 NIATSLV 7.6 S502 EQT.LMSKNVICY 10.54 
L218 LAVIM 7.22 H503 .HRGSMNKQY 7.01 
H219 IMRKFAHSQY 9.14 W504 .YTPWLA 4.8 
N220 SQKENHYL 9.73 P505 .FPALSEM 4.29 
L221 LPISVFM 9.4 L506 .NSVLI 5.95 
S222 NTESVLCAY 8.87 I507 .VILA 7.59 
H223 K.NHRQLTPEDYCS 13.23 K508 TRAQK. 5.49 
H224 D.NSQTHRGLKMY 11.61 A509 KMLVSQH.A 5.27 
R225 P.EVTYRQKSA 11.49 T510 TPELQA.VIM 12.67 
E226 H.QDENVPTASG 11.24 V511 AIMVSL.C 10.99 
G227 M.ISAG 5.55 G512 GNKTALQ.S 4.47 
L228 K.SRVILAP 8.36 L513 PEQVTSIL. 8.02 
L229 NKRLAIEDMTSV 11 I514 NYVTSMQLIF 12.55 
A230 QAVFDLSNHIG 10.77 R515 EKRQLVN 5.71 
I231 VTIML 8.18 N516 KQACREN 5.61 
F232 FVAHRKLTWQY 7.68 L517 QVLTAICS 6.08 
K233 QDHERTNKA 10.68 A518 QGAIPSVE 5.68 
S234 IMLAP.SEVYC 10.03 L519 VAQELPSRM 6.98 
G235 .GDEVIFNRQST 10.17 C520 CRAVEDLQGSNTY 11.03 
G236 .GRNSFVC 5.42 P521 KRTECPDNGALISQ 10.24 
I237 FLIV 8.77 A522 EDSRCVAQKHGT 12.6 
P238 NEQPDTA 7.73 N523 IEDNASFLC 7.81 
A239 CNSTPKIHDEVFA 13.25 H524 D.MRASLQIFHYV 8.88 
L240 ILMV 6.46 A525 IVFASEPHRKYTGQ 15.61 
V241 ILVYSC 6.28 P526 LIEDPGSVRFA 8.71 
K242 MKQEAHRDN 13.17 L527 KILFHM 5.96 
M243 GCYILSQFHM 10.57 R528 KRDQLSNIYG 12.48 
L244 VLSTMI 5.56 E529 DQKSNGPE 10.21 
G245 .NDRKAEGSTY 12.34 Q530 TVLAYIDKCQNHE 11.91 
S246 .NSDMTFHYVI 9.82 G531 PVADGTSN 11.61 
P247 .PDEVSAFTNQR 10.85 A532 GPNVFTILCA 10.54 
V248 KVDFLISPGM 10.91 I533 LVIETGM 8.72 
D249 NYKPALDFGEM 10.29 P534 LMRQEPFNHYWTAS 12.85 
S250 EDVITSAKNP 8.3 R535 ELPNQRGSTHK 10.58 
V251 KLIHVSA 3.98 L536 LVASNI.MT 9.36 
L252 LKQYIVFR 6.44 V537 RWVIQ.TCFM 8 
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Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
F253 HSNACKYRTEF 10.56 Q538 SNMLIH.EQVTRD 10.29 
Y254 LMICYTF 5.82 L539 TLMIV.AY 4.5 
A255 KASTV 4.24 L540 ILS.FC 2.76 
I256 FYALPMVI 8.48 V541 LKHQTR.YNISMVFAG 14.44 
T257 EMKLYTSN 6.36 R542 RNSTV.QAK 5.8 
T258 KRTALS 5.62 A543 SFPQYGA.TI 9.52 
L259 LMVIF 6.69 H544 FSNHYPC.TQVIG 12.67 
H260 VIFAQDRKHN 9.15 Q545 IFLAPKDEHT.QNY 15.61 
N261 GQNRHST 7.55 D546 LDESYQ.TGHMA 6.76 
L262 TAVILM 6.11 T547 LVSF.AIYNT 10.96 
L263 LATSFIM 4.19 Q548 LSQREIPN.TKD 13.16 
L264 SLRKTQAWYIM 11.6 R549 RSAHEQPV.DGNK 11.68 
H265 EGRFDQVHY 11.08 R550 PAVKQE.STR 9.47 
Q266 FL.VRSQIPHM 8.96 T551 FSACQTVM.LGR 14.74 
E267 NGDRKSEPAVQ 13.54 S552 VMIWLTAG.QCSHPN 15.87 
G268 PQRDESLGY 10.51 M553 PAITL.SRKVMN 12.93 
A269 QTANPDSG 10.42 G554 KALIR.TNSDG 13.79 
K270 VILRATQK 9.02 G555 DECSAT.INMPG 13.03 
M271 HPRISVDANELMQTG 14.85 T556 GVSPLAT.DIQN 16.19 
A272 PLTAQVMEIDS 11.35 Q557 VFLCRDI.TNEAGPQSM 15.97 
V273 GSPVFLRIAT 10.8 Q558 LFRKIP.GMNSAQTDE 16.97 
R274 MQLRC 4.65 Q559 NGRS.EPLTAKQI 15.67 
L275 ILQDEHGRANKSM 14.55 F560 VLF.IHKWSNMRYA 14.43 
A276 NYHELQKSRAC 11.09 V561 ITVFLDSHR.QAN 12.7 
G277 PGQETHDSNL 9.07 E562 DGEKRQ.N 5.06 
G278 ATGVLIC 7.68 G563 EDGAKRLNS. 8.28 
L279 IVFMLTH 7.81 V564 NFLMRVIK. 6.92 
Q280 FLKESTNIQPV 9.71 R565 RKEDA.LSYQP 11.64 
K281 IVLKFRPHAGCN 9.36 M566 KRILHTV.MS 6.46 
M282 IVLASM 9.3 E567 EKRVQLA.DSNMW 10.34 
V283 FLVMITAYS 10.64 E568 NSED.G 6.56 
A284 RKGDQHEPSATNY 13.52 I569 LVI.MF 5.76 
L285 FLINSVWQKPH 8.66 V570 IVL.M 7.44 
L286 ILVSM 4.66 E571 GANDKEVHQ.W 5.26 
N287 IDSANKREQVH 13.05 G572 HSARLGEVC 5.49 
K288 D.EAPRIYKH 10.08 C573 IVNSGTCA 11.23 
T289 RVQCNHSTKDPG 15.03 T574 CALVMFIT 9.72 
N290 LIV.KNSAD 7.1 G575 AISGRQVKCN 8.43 
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Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
V291 KPTMERVIY 8 A576 AVLCITE 4.85 
K292 DNIEKRQ 7.98 L577 YLFIK 5.18 
F293 YCGLVWNF 11.36 H578 SCAYTHRQE 6.61 
L294 FLMASNKYIV 8.3 I579 WKNSLAMIVQ 7.99 
A295 ISADGPVT 6.3 L580 VAILTM 5.72 
I296 WLTFIVMQ 6.49 A581 FDYATCGS 8.1 
T297 NGTSHALICVD 13.49 R582 RGKSCN 8.95 
T298 NPKAVFLIT 11.74 D583 QDHKE 8.11 
D299 NDEMS 8.2 V584 PKQELGAR.NHFISV 18.26 
C300 PRQAICLTSG 11.17 H585 NTEASKRDH.LGYFVMIQ 15.77 
L301 ILAV 5.72 N586 NSPVLI.AT 7.21 
Q302 IMLQKHRY 7.79 R587 TELSR.KA 6.51 
I303 KLAVNIMF 10.49 I588 QKADNET.SLMGI 16.49 
L304 LVTI 2.81 V589 SDVILAEQ.YTF 16.78 
A305 VICLSAT 9.2 I590 TLIV.CM 6.99 
Y306 MLVSRYEDFHAI 11.24 R591 KRTSEIVA.DNYFQCL 13.63 
G307 IMLKSETRGDNA 11.27 G592 QN.DHYFCRSLGAKE 16.38 
N308 GRSDNH 8.75 L593 Q.GVLHFTEPMD 8.79 
Q309 SCTKIAPEHNVYQG 13.78 N594 L.FVANIKMDQSRH 10.69 
E310 YEHKRADSNPQ 12.32 T595 VI.YAHLQRGSTC 14.35 
S311 RHQNSITEAGK 9.36 I596 IFVANL.T 8.88 
K312 LMQKFR 7.43 P597 SPRTG.QHFAD 6.45 
L313 ILMGEQYRNK 13.15 L598 LMPAIT.SV 10.57 
I314 .RALMKTQEIVS 10.68 F599 LGN.FTVI 7.86 
I315 .NIMAFLV 7.87 V600 LVIAQTNSC.MHY 10.5 
L316 .SRHKQLVA 7.83 Q601 VRKPHL.QSE 8.78 
A317 .QKEDRPLGACS 12.77 L602 LIF.EQYMC 6.88 
S318 .IAGTMFLCSHN 12.05 L603 MITL.QKV 8.15 
G319 .AGDNHSQTL 11.56 Y604 Q.PYARINFHSG 11.21 
G320 ANSGVIL 7.82 S605 G.NDQTIESVMFR 11.59 
P321 GFVILPAHS 7.72 P606 ADETSMPQ.NHVR 16.03 
Q322 QPHTKNRASELVGMI 19.01 I607 ETVLISCD.NH 11.47 
A323 NDLRIFKHEAQGS 12.32 E608 KVED.QIG 9.3 
L324 PQLFV 3.7 N609 EQDSNP.RGHVL 10.61 
V325 EMGAVLFI 10.15 I610 VRKLYIMT. 9.16 
N326 TSRKEADLHQN 16.34 Q611 ALSCMTK.QHVE 8.64 
I327 LMVFI 8.03 R612 QHRKPYGS.L 7.67 
M328 PNLIMV 9.88 V613 YSGRQEP.AVF 9 
168 
 
Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
R329 QR.KETD 10.33 A614 SLHPEWAT.CVI 9.02 
T330 N.EDRHTQSAIM 12.51 A615 YLVK.AST 5.68 
Y331 .FKETCRLHYS 8.95 G616 STGAVE.NK 9.97 
T332 EDP.SNGRTQIH 15.99 V617 IHRSTF.LVGA 8.25 
Y333 LMHN.PDYQV 8.11 L618 DSCQIL.V 5.92 
E334 ASKE.GPR 7.32 C619 CSLIQY.AV 8.51 
K335 HMRN.EDKGY 7.51 E620 PINVASQME.LK 9.06 
L336 LM.AFV 4.88 L621 LWFSIP.MV 5.65 
L337 IALVT 6.94 A622 NSGCIMA.VE 10.32 
W338 QITWMYF 4.72 Q623 LMSNTCQH.EGVAK 16.49 
T339 VPTRNA 3.04 D624 L.ETHPSYDR 8.17 
T340 IVNTGA 6.37 K625 NK.TLEPARD 10.34 
S341 ITVLMSAC 7.48 E626 VMI.EDQHGANL 10.57 
R342 RGSPQK 4.24 A627 K.NLVMGCFRYAS 10.16 
V343 TSAEDLCV 8.69 A628 PNISCGLA.MV 7.18 
L344 FLIVM 4.09 E629 TQLREKSDA.VGH 12.53 
K345 DQKTRV 4.36 A630 FATKLIV.QMS 15.93 
V346 LESMTAVQ 8.07 I631 ISANYCL.V 7.86 
L347 LCNFMI 4.62 E632 NGSFLATREKD 9.62 
S348 GNACS. 4.42 A633 VDRSGLIWTQNAEM 15.54 
V349 LSVA.T 3.87 E634 LAEKTQDNIPCY 10.26 
C350 DEKLASC 5.36 G635 VRGASQMWTPN 8.05 
S351 SEPCAN.TLHQV 12.92 A636 VASLYFRIGP 9.05 
S352 DNSIEAFH.KQM 11.48 T637 CSVDRNYMEFTGPA 14.17 
N353 AYNKSDL 4.02 A638 DAVTILHQKSPENG 13.4 
K354 IRKGLPA 3.85 P639 KPGTNVMAERLYI 9.87 
P355 DILVSNPQHTKA 9.69 L640 ILERQTVF 6.15 
A356 GAREVSNLKIC 7.79 T641 LVEDYQFTSGNMIA 8.97 
I357 FILV 4.41 E642 EQRKGDFATNH 10.97 
V358 VQRHSMIL 6.22 L643 HYQKLFTVAMS 7.94 
E359 RKNTEVSAQD 13.12 L644 CSLGQRA.IV 10.4 
A360 SLAEQDCFKTI 11.14 H645 PKNGTCR.HQI 7.87 
G361 DGNEKSA 5.15 S646 TMLSPRA.F 8.01 
G362 GMVASC 6.02 R647 RLKQPSN.HTA 13.39 
M363 VIEALPRYM 7.82 N648 ADERNQYH 7.06 
Q364 GQKESFDALVPI 13.02 E649 DNKETARSQMP 12.06 
A365 ALMDVFI 8.96 G650 IGSANDRQYK 11.2 
L366 IL 1.19 V651 WVTMGKCISFLE 10.16 
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Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
G367 TYCVIHASGL 13.79 A652 TSAHIN.VLQ 10.19 
L368 TKEHGRNPSLQAVMD 13.79 T653 ITQRKPE.GAS 9.11 
H369 VINLCRQHYF 8.83 Y654 DYSGR.HMT 6.78 
L370 VILFKMC 5.83 A655 RSTDVI.PA 7.37 
T371 QNSKVERDYHGATP 16.34 A656 .ACDRPQNSG 7.36 
D372 YSVHCATGDN 9.72 A657 .MRTPNGYAIVL 8.44 
P373 PQDAEGKTSRNHMV 15.6 V658 PSGATKYLNVI 11.78 
S374 NSDE 4.92 L659 MTLPSIRNV 6.95 
Q375 NSTDVALPQEHG 17.53 F660 LVYRKDMNPHIFS 12.8 
R376 DNESRF 6.13 R661 ERQKSVCHN 10.12 
L377 LVTS 5.18 M662 GMLKIFAT 10.28 
V378 IVAQKLRTM. 10.07 S663 LFSKEI.TNAQ 11.92 
Q379 RMTHYALIEQ.F 9.22 E664 TKEGDNHY.LARF 11.26 
N380 ASHENCT. 7.37 D665 NDE.KPSVG 9.23 
C381 GCTALISV. 8.07 K666 .KRHGQED 6.45 
L382 CFAL. 4.81 P667 .LSPVNRK 9.89 
W383 KSQGWEAYFD.VC 5.83 Q668 .QAPEDKGVSMHT 13.84 
T384 LACTS. 6.16 D669 .PLIDERNAVM 10.92 
L385 LIVM.C 6.52 Y670 .WFGYSHVLT 9.68 
R386 LFDGR. 3.42 K671 H.KNCDARSL 11.92 
N387 QKAVN. 4.24 K672 RS.MPQKDEGFNT 13.45 
L388 VCMLI. 3.77 R673 N.MPQRSTHGAE 7.67 
S389 SA. 2.31 L674 SPDTQLYMHFVIA 13.87 
D390 DQEFN. 4.61 S675 DNEQFLRSPATI 9.58 
A391 ASDEHNLVYMC. 11.53 V676 INVSLCPTHGMYA 12.56 
A392 KRLPAVSGH. 9.01 E677 AECSNQRHP.D 10.45 
T393 ASQELVTYKRN. 10.33 L678 KRQILNHY.VM 10.34 
K394 LTSIDPKNHGR. 8.83 T679 ATQVRDP.FGNSE 10.22 
Q395 KLRNYGHDEIMQVT. 14.26 S680 AVMLKQRN.EPTGSH 15.42 
E396 TIDQSKLVAN.EP 13.13 S681 SGEVIQN.AP 9.25 
G397 PNLSDVEGHATQ 11.42 L682 LKAEMQ.TPVIY 9.62 
M398 LVFIMA.HTQ 10.28 F683 LGEF.YPAHCD 11.16 
E399 EKRGTDSAQ 13.59 R684 SARVM.LPDGHQKFY 13.12 
G400 NEQDHPIMVTKGSA 19.19 T685 RKVT.EPQINSDHGA 16.36 
L401 IPTYLWSV 8.56 E686 FLKQE.SNDVMA 13.26 
L402 LIV 4.33 P687 EDHKP.STNGAQ 17.2 
G403 PQDHLSKTIMRVG 13.75 M688 NSAIML.TGVPEHQ 19.68 
T404 FPASNQKRHVITMG 15.89 A689 DAQMVS.TLEPNI 18.56 
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Table 4S.1. Continued. 
Residue Variations rvET scores Residue Variations rvET scores 
L405 LIV 6.19 W690 LMGDT.RYFWEI 8.66 
V406 LMIVT 9.19 N691 LDSEA.GTFNPQM 15.34 
Q407 RQASKMGCEDHNTL 16.89 E692 AEDQRT.GHSLPMN 20.16 
L408 LRIVFSQM 9.34 T693 .ATYSNPVGQELD 11.66 
L409 ILCVF 9.36 A694 .RQKPNEDASTH 11.3 
G410 ERGSQNKAMDT 15.99 D695 .LFDPQNGEV 10.02 
S411 HNATDSCPERGLVQI 16.55 L696 .LVPSGYMNIF 10.16 
D412 PGENDSRVTAKQ 16.53 G697 .QSATRLGHCFDE 12.05 
D413 DENSQ 6.35 L698 .EDMHQLANV 20.16 
I414 DKLGVPAREITSM 14.03 D699 .AKHTNSQDEF 9.9 
N415 EDQVTIAYNHSG 14.28 I700 .ASMQPLIV 20.16 
V416 VILTMYS 11.92 G701 .AGDHSPLNT 20.16 
V417 IVLKSRATN 10.81 A702 ILNMKA.DVCSYGT 15.74 
T418 YAEQLMIT 5.12 Q703 FLIEGQMP.VHSTA 14.17 
C419 SARCYF 2.5 G704 SHQRKP.TEDGLA 15.31 
A420 GAICSV 5.66 E705 NTLRQP.EYDSIMHGA 16.07 
A421 TLVGAMSC 10.41 P706 RSH.PQIADTNEM 15.82 
G422 GQLD 3.42 L707 FT.PSHGVRADLQE 18.75 
I423 FAVSICT 8 G708 .EDWLSHGAPVT 16.16 
L424 LIM 3.54 Y709 .GLHSERYNT 11.74 
S425 SWARGC 3.43 R710 .AHPQGMILRSYF 14.83 
N426 NK 1.57 Q711 .LQVMSNYGAPDT 14.24 
L427 VCLIM 3.08 D712 .ASNKVTQDMEGP 14.24 






FUTURE DIRECTIONS AND CONCLUSION 
 
5.1 Future directions of novel β-catenin/Tcf inhibitors  
Compounds 14 and 37 showed the ability of the 5H-[1,2,5]oxadiazolo-
[3’,4’:5,6]pyrazino[2,3-b]indole (31) scaffold to inhibit the β-catenin/Tcf PPI.1 
Compound 37 achieved a 3.12 µM Ki in the FP assay and disrupted the canonical Wnt 
signaling pathway in zebrafish at a 10 µM concentration.2,3 Compound 14 achieved a 17 
µM Ki in the FP assay and a 20 µM IC50 against β-catenin-dependent colorectal cancer 
cell growth.1 Despite these promising results, the removal of the acyl hydrazone PAIN 
structure was only the first step in the optimization of the compound. A 6H-indolo[2,3-
b]quinoxaline (44) scaffold was developed to increase the synthetic yield of the first 
reaction, resulting in final compounds 48 and 49. Compound 48 achieved a 67 µM Ki in 
the FP assay, and induced cell cycle arrest in MECs.4 Compound 48 lost some activity 
compared to 14; this is most likely due to the loss of a hydrogen bond between the 
furazan moiety and K508 of β-catenin. The SAR study is aimed at expanding the 
inhibitor into the hydrophobic pocket B and increasing potency. Compound 49 illustrates 
the potential for increased potency from this expansion. Finally, the molecule has low 
solubility in most solvents and the large flat scaffold may cause DNA intercalation. 
Therefore, further modifications are needed to increase efficacy and further develop drug-
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like properties of the molecule: reinstatement the second hydrogen bond with K508; 
completion of the SAR of both the isatin and phenyldiamine moieties; and addition of 
more sp3-hybridized carbons to the scaffold. Figure 5.1A illustrates potential substitutions 
which will be used and synthesized in a similar manner as scheme 4. With the inclusion 
of o-phenylenediamine, substitutions on the 3-, 4-, 5-, and 6-positions of the starting 
material are possible. Figure 5.1B shows potential o-phenylenediamine substitutions. 
Schemes 5-8 (Figure 5.2) present three synthetic routes to increase the number of sp3-
hybridized carbons to the scaffold or reinstate the hydrogen bond with K508. Figure 5.3 
shows the predicted binding mode of the new compounds which differ from the original 
predicted binding mode of 14. Once these studies are completed, a more complete battery 
of in vivo testing will be appropriate. 
 
5.2 Practical applications of θl to the discovery of  
PPI inhibitors 
 Preliminary examination of the solvent exposed surface area of PPI inhibitors 
revealed a small, but significant, correlation between ligand burial (θl) and inhibitor 
potency in a limited test set. The two test proteins, Bcl-XL and MDM2 were selected 
because of the large quantity of structural data available for protein-inhibitor complexes. 
It was hypothesized that if more protein-inhibitor complexes were examined, the 
relationship between θl and inhibitor potency would become clearer. θl alone was unable 
to identify a single correct inhibitor out of a putatively inactive test set. This result is not 
unexpected because the docking programs showed only mediocre performance in 




Figure 5.1. Potential substitutions based on available isatin (A) and o-phenylenediamine 




Figure 5.2. Schemes 5–8.  
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Figure 5.3. Predicted binding modes of proposed compounds. Because of the substitution 
of the benzene ring for a hexane ring, the binding mode of the inhibitor is reversed so that 
the aromatic ring interacts with R469. 
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ancillary property when selecting HTVS results to test. However, docking score, 
pharmacophore fit, and hot spot interactions in particular should remain the primary 
criteria for inhibitor selection. Therefore, to validate θl as an important property for 
HTVS of PPIs, there is a need to expand the limited samples that were used to establish 
its importance and apply θl to a novel HTVS.  
The first objective is to review more protein-inhibitor complexes to strengthen the 
relationship between θl and potency. The first step would be to evaluate other MDM2 
inhibitors, of which there are many with no crystal or NMR structures. These would need 
to be treated like the Bcl-XL inhibitors, which were first docked, then evaluated. The 
second objective is to look for other PPI inhibitor crystal structures with large data sets. 
Examples include calmodulin, a messenger protein,6 and BRD4, a bromodomain protein.7 
By examining inhibitors of these proteins, the relationship between θl and potency could 
be strengthened. 
The second direction of the study would be developing a practical use for θl for 
improvement of HTVS of PPIs. This would be explored by incorporating it into a novel 
HTVS of a PPI. This would be accomplished by using the Bcl9 binding site on β-catenin. 
The Bcl9 binding site is shallow and lacks many deep pockets, which makes it a typical 
PPI binding surface. Drug-like, PAINs-free8 ligands from the ZINC library9 would be 
docked into the Bcl9 binding site using AutoDock Vina10 and Schrödinger Glide.11-13 A 
pharmacophore model would be created from the inhibitor 3',4'-difluoro-N-(4'-fluoro-2-
(((R)-pyrrolidin-3-yl)oxy)-[1,1'-biphenyl]-4-yl)-6-(((S)-pyrrolidin-3-yl)oxy)-[1,1'-
biphenyl]-3-carboxamide14 developed by Logan Hoggard et al.14 This inhibitor was 
designed to mimic the i, i+3 and i+7 interactions of the projecting hot spots of the Bcl9 
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helix-2.14 This compound had a Ki of 2.1 + 0.4 μM and was selective for the β-
catenin/Bcl9 interaction over the β-catenin/E-cadherin PPI.14 Two test sets of highly 
scored docked ligands that would be a good match to the pharmacophore model would 
have their solvent-exposed surface areas analyzed. These values would aid in the 
selection of molecules to test. Two separate test sets of significant size would be 
evaluated. One set would be picked with the aid of θl and one set would be picked 
without the aid of θl. It is hypothesized that there will be more effective inhibitors in the 
former set and fewer effective inhibitors in the latter set. The results of this would help 
further the understanding of the practical applications and limits of using solvent-exposed 
surface areas as a means to evaluate potential PPI inhibitors, as well as yield a new 
inhibitor of the β-catenin/Bcl9 PPI. 
 
5.3 Further validation of potential allostery of the W504 pocket 
 ET analysis15 identified the region surrounding β-catenin W504 as a functionally 
important residue. This is unusual because it had no contacts with any known β-catenin 
binding partner. Analysis of the β-catenin MD simulation with FTMap16 revealed 
potential druggability of this site. Mutations of W504 produced an increased binding of 
β-catenin to Tcf, indicating potential allosteric communication between the W504 site 
and nearby hot region 1.  
While evidence supported that the W504 pocket may be able to allosterically 
communicate with hot region 1, the evidence is still preliminary. Therefore, the next step 
would be to carefully evaluate that the site is indeed allosterically connected to hot region 
1. The discovery of a small molecule capable of binding to the W504 binding site would 
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greatly enhance the significance of the W504 site. The small molecule may have a 
stronger effect on Tcf binding than the single point mutants of W504. This site would be 
an ideal target for an ensemble docking-based HTVS because many of the druggable 
conformations were discovered by an MD simulation. The MD simulation snapshots 
would be used generate the ensemble of structures for docking. The inclusion of receptor 
flexibility would allow for a conformation that can maximize interactions,17 and would 
reduce the entropic penalty of binding by "softening" the protein surface.17 Also, the MD 
simulation would allow for receptor conformations that exist only briefly to be sampled 
for docking.17 The surface characteristics of the W504 pocket are aligned with those of a 
typical PPI surface. Therefore, this study would present an opportunity to apply the 
lessons learned in Chapter 3. Any inhibitor found would need to be well scrutinized to 
ensure binding to the W504 pocket and no other regions of β-catenin. Once a potent 
allosteric inhibitor is discovered, further study must be made into the mechanism of 
allosteric communication between the W504 region and hot region 1. 
 The mechanism of allosteric communication between the W504 pocket and hot 
region 1 is unknown. One possibility would be that W504 mutations affect hot region 1 
through helix 8 of β-catenin. W504 is positioned at the end of this helix, and the 
disruption of these residues might be conveyed through the helix to key residue K508. 
The physical effects of the W504 mutation on Tcf binding would be examined through 
NMR18 and MD simulations.19 Understanding the mechanism of allostery would aid in 
designing small-molecule allosteric modulators that can inhibit, instead of enhance, Tcf 
binding.  
 β-catenin has over 100 direct interacting partners20. Therefore, quantitative 
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affinity pull-down mass-spectrometry (q-AP-MS) or “shotgun” proteomics would be a 
good method to characterize the potential allosteric or orthosteric effect of the W504 
mutants at the same time (Figure 5.4).21,22 An F9 β-catenin null cell line will be used to 
generate comparative cell lysates of both WT β-catenin and W504A mutants. The cell 
lysates will be digested and purified using HPLC and analyzed through mass 
spectrometry. The mass spectrometry data can be analyzed computationally to give 
quantitative information about changes in bound β-catenin populations. This experiment 




In summary, the research presented here will help further the development of PPI 
inhibitors. These PPI inhibitors could act as small-molecule therapeutics or as probes 
which could aid in further discoveries about the natures of PPIs. The PPI interface is 
large and featureless which is problematic for small-molecule inhibitors23. As a result, 
multiple methods have been developed to aid in drugging the undruggable. Chief among 
these is the use of hot spots.24  
 One example of a PPI is the β-catenin/Tcf interaction. The β-catenin/Tcf PPI is a 
key mediator of the canonical Wnt signaling pathway.25 This research presents a new 
series of small-molecule inhibitors that selectively inhibit the β-catenin/Tcf PPI. These 
compounds utilized the hot spots K435 and K508 to selectively disrupt the β-catenin/Tcf 
PPI. These compounds showed good results in vitro and in vivo. Further optimization of 
this compound requires consideration of the drug-like properties of this molecule.  
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Figure 5.4. Diagram of q-AP-MS proteomics for β-catenin . Figure derived from methods 
described by Dunham et al.22 
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The research presented here examined the relationship of SASA and suitability of 
common docking algorithms for PPIs. The property, θl, was first discussed by 
Gowthaman et al.26 This property was further explored to find a small, yet significant, 
correlation between θl and inhibitor potency. Because hot spots are often buried in the 
PPI interface, it was hypothesized a more buried ligand should have a better chance at 
interacting with hot spots. This was indeed the case, but θl was still overshadowed by 
other, stronger, nonbonding interactions. 
 Lastly, the origins of β-catenin binding partner selectivity and a potential for 
latent allostery in the ARM domain of β-catenin was explored through ET analysis. This 
analysis revealed the region around W504 as a potential allosteric site. This potential for 
allosteric regulation needs to be carefully validated before it may prove of use. 
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